Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
Transplantation of an individual's own tissue from one site to another site.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
The transference of a part of or an entire liver from one human or animal to another.
Progenitor cells from which all blood cells derive.
An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.
Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS).
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
The transference of a kidney from one human or animal to another.
Transference of cells within an individual, between individuals of the same species, or between individuals of different species.
Cells derived from the BLASTOCYST INNER CELL MASS which forms before implantation in the uterine wall. They retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
Cells with high proliferative and self renewal capacities derived from adults.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
The return of a sign, symptom, or disease after a remission.
Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Therapeutic act or process that initiates a response to a complete or partial remission level.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
Immunological rejection of leukemia cells following bone marrow transplantation.
The transference of a heart from one human or animal to another.
Cells that can give rise to cells of the three different GERM LAYERS.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
The transference of either one or both of the lungs from one human or animal to another.
A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.
A particular zone of tissue composed of a specialized microenvironment where stem cells are retained in a undifferentiated, self-renewable state.
Self-renewing cells that generate the main phenotypes of the nervous system in both the embryo and adult. Neural stem cells are precursors to both NEURONS and NEUROGLIA.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Elements of limited time intervals, contributing to particular results or situations.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Bone-marrow-derived, non-hematopoietic cells that support HEMATOPOETIC STEM CELLS. They have also been isolated from other organs and tissues such as UMBILICAL CORD BLOOD, umbilical vein subendothelium, and WHARTON JELLY. These cells are considered to be a source of multipotent stem cells because they include subpopulations of mesenchymal stem cells.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Cells from adult organisms that have been reprogrammed into a pluripotential state similar to that of EMBRYONIC STEM CELLS.
Transference of an organ between individuals of the same species or between individuals of different species.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains.
Persons or animals having at least one parent in common. (American College Dictionary, 3d ed)
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
Disorders of the blood and blood forming tissues.
The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.
Specialized stem cells that are committed to give rise to cells that have a particular function; examples are MYOBLASTS; MYELOID PROGENITOR CELLS; and skin stem cells. (Stem Cells: A Primer [Internet]. Bethesda (MD): National Institutes of Health (US); 2000 May [cited 2002 Apr 5]. Available from:
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.
Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Cells derived from a FETUS that retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
The developmental history of specific differentiated cell types as traced back to the original STEM CELLS in the embryo.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
Providers of tissues for transplant to non-related individuals.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
A hematopoietic growth factor and the ligand of the cell surface c-kit protein (PROTO-ONCOGENE PROTEINS C-KIT). It is expressed during embryogenesis and is a growth factor for a number of cell types including the MAST CELLS and the MELANOCYTES in addition to the HEMATOPOIETIC STEM CELLS.
Non-cadaveric providers of organs for transplant to related or non-related recipients.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
The transference of a pancreas from one human or animal to another.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
Disease having a short and relatively severe course.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor.
The procedure established to evaluate the health status and risk factors of the potential DONORS of biological materials. Donors are selected based on the principles that their health will not be compromised in the process, and the donated materials, such as TISSUES or organs, are safe for reuse in the recipients.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an X-linked or autosomal recessive defect. Mutations occurring in many different genes cause human Severe Combined Immunodeficiency (SCID).
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
The physiological renewal, repair, or replacement of tissue.
An induced state of non-reactivity to grafted tissue from a donor organism that would ordinarily trigger a cell-mediated or humoral immune response.
Experimentation on STEM CELLS and on the use of stem cells.
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Allelic alloantigens often responsible for weak graft rejection in cases when (major) histocompatibility has been established by standard tests. In the mouse they are coded by more than 500 genes at up to 30 minor histocompatibility loci. The most well-known minor histocompatibility antigen in mammals is the H-Y antigen.
Transplantation between animals of different species.
A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Methods for maintaining or growing CELLS in vitro.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Substances that inhibit or prevent the proliferation of NEOPLASMS.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
The mechanism by which latent viruses, such as genetically transmitted tumor viruses (PROVIRUSES) or PROPHAGES of lysogenic bacteria, are induced to replicate and then released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell LIPOPOLYSACCHARIDES, glucocorticoid hormones, halogenated pyrimidines, IONIZING RADIATION, ultraviolet light, and superinfecting viruses.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery.
Transference of fetal tissue between individuals of the same species or between individuals of different species.
A general term for various neoplastic diseases of the lymphoid tissue.
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.
Euploid male germ cells of an early stage of SPERMATOGENESIS, derived from prespermatogonia. With the onset of puberty, spermatogonia at the basement membrane of the seminiferous tubule proliferate by mitotic then meiotic divisions and give rise to the haploid SPERMATOCYTES.
Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues.
A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
Transplantation of tissue typical of one area to a different recipient site. The tissue may be autologous, heterologous, or homologous.
An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).
Parts of plants that usually grow vertically upwards towards the light and support the leaves, buds, and reproductive structures. (From Concise Dictionary of Biology, 1990)
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Tissues, cells, or organs transplanted between genetically different individuals of the same species.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
Antibodies obtained from a single clone of cells grown in mice or rats.
Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor.
The simultaneous, or near simultaneous, transference of heart and lungs from one human or animal to another.
The administrative procedures involved with acquiring TISSUES or organs for TRANSPLANTATION through various programs, systems, or organizations. These procedures include obtaining consent from TISSUE DONORS and arranging for transportation of donated tissues and organs, after TISSUE HARVESTING, to HOSPITALS for processing and transplantation.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
Antibodies produced by a single clone of cells.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Infection with ROSEOLOVIRUS, the most common in humans being EXANTHEMA SUBITUM, a benign disease of infants and young children.
Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA.
A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
The number of LYMPHOCYTES per unit volume of BLOOD.
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
An anti-inflammatory 9-fluoro-glucocorticoid.
The cells found in the body fluid circulating throughout the CARDIOVASCULAR SYSTEM.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
The number of CELLS of a specific kind, usually measured per unit volume or area of sample.
A family composed of spouses and their children.
The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.
A field of medicine concerned with developing and using strategies aimed at repair or replacement of damaged, diseased, or metabolically deficient organs, tissues, and cells via TISSUE ENGINEERING; CELL TRANSPLANTATION; and ARTIFICIAL ORGANS and BIOARTIFICIAL ORGANS and tissues.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Infections with fungi of the genus ASPERGILLUS.
The transfer of leukocytes from a donor to a recipient or reinfusion to the donor.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
Inorganic or organic compounds that contain the basic structure RB(OH)2.
Pathological processes of the LIVER.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
An individual that contains cell populations derived from different zygotes.
Non-invasive imaging of cells that have been labeled non-destructively, such as with nanoemulsions or reporter genes that can be detected by molecular imaging, to monitor their location, viability, cell lineage expansion, response to drugs, movement, or other behaviors in vivo.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.
A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives.
The grafting of skin in humans or animals from one site to another to replace a lost portion of the body surface skin.
A decrease in the number of NEUTROPHILS found in the blood.
A PREDNISOLONE derivative with similar anti-inflammatory action.
An octamer transcription factor that is expressed primarily in totipotent embryonic STEM CELLS and GERM CELLS and is down-regulated during CELL DIFFERENTIATION.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Transference of tissue within an individual, between individuals of the same species, or between individuals of different species.

Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. (1/3936)

Myoblasts, the precursors of skeletal muscle fibers, can be induced to withdraw from the cell cycle and differentiate in vitro. Recent studies have also identified undifferentiated subpopulations that can self-renew and generate myogenic cells (Baroffio, A., M. Hamann, L. Bernheim, M.-L. Bochaton-Pillat, G. Gabbiani, and C.R. Bader. 1996. Differentiation. 60:47-57; Yoshida, N., S. Yoshida, K. Koishi, K. Masuda, and Y. Nabeshima. 1998. J. Cell Sci. 111:769-779). Cultured myoblasts can also differentiate and contribute to repair and new muscle formation in vivo, a capacity exploited in attempts to develop myoblast transplantation (MT) for genetic modification of adult muscle. Our studies of the dynamics of MT demonstrate that cultures of myoblasts contain distinct subpopulations defined by their behavior in vitro and divergent responses to grafting. By comparing a genomic and a semiconserved marker, we have followed the fate of myoblasts transplanted into muscles of dystrophic mice, finding that the majority of the grafted cells quickly die and only a minority are responsible for new muscle formation. This minority is behaviorally distinct, slowly dividing in tissue culture, but rapidly proliferative after grafting, suggesting a subpopulation with stem cell-like characteristics.  (+info)

Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells. (2/3936)

Multipotent and self-renewing neural stem cells have been isolated in culture, but equivalent cells have not yet been prospectively identified in neural tissue. Using cell surface markers and flow cytometry, we have isolated neural crest stem cells (NCSCs) from mammalian fetal peripheral nerve. These cells are phenotypically and functionally indistinguishable from NCSCs previously isolated by culturing embryonic neural tube explants. Moreover, in vivo BrdU labeling indicates that these stem cells self-renew in vivo. NCSCs freshly isolated from nerve tissue can be directly transplanted in vivo, where they generate both neurons and glia. These data indicate that neural stem cells persist in peripheral nerve into late gestation by undergoing self-renewal. Such persistence may explain the origins of some PNS tumors in humans.  (+info)

Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. (3/3936)

Many patients have not been offered potentially curative allogeneic marrow transplants because of the toxicity of myeloablative regimens in the setting of advanced age or organ dysfunction. We treated five patients, ineligible for myeloablative chemotherapy due to one of these criteria, with fludarabine-based non-myeloablative chemotherapy followed by reinfusion of G-CSF-mobilised allogeneic peripheral blood progenitor cells (PBPC). Two patients died early of multi-organ failure. Another patient with massive splenomegaly was infused with a suboptimal number of PBPC; no engraftment was documented. The remaining two patients demonstrated mixed chimerism early post-transplant, but by 3 and 6 months respectively, engraftment was almost entirely of donor origin. One of these patients, transplanted with relapsed AML, remains in remission with extensive chronic GVHD at 17 months. The other patient, transplanted with chemorefractory mantle cell lymphoma, progressed early post-transplant but entered remission coincident with the onset of severe GVHD following cessation of cyclosporin A, suggesting a powerful graft-versus-mantle cell lymphoma effect. These preliminary observations suggest this approach results in engraftment and GVHD/graft-versus-tumour effects similar to myeloablative regimens and may provide an alternative in patients ineligible for conventional conditioning regimens.  (+info)

Pattern and kinetics of mouse donor spermatogonial stem cell colonization in recipient testes. (4/3936)

Recently a system was developed in which transplanted donor spermatogonial stem cells establish complete spermatogenesis in the testes of an infertile recipient. To obtain insight into stem cell activity and the behavior of donor germ cells, the pattern and kinetics of mouse spermatogonial colonization in recipient seminiferous tubules were analyzed during the 4 mo following transplantation. The colonization process can be divided into three continuous phases. First, during the initial week, transplanted cells were randomly distributed throughout the tubules, and a small number reached the basement membrane. Second, from 1 wk to 1 mo, donor cells on the basement membrane divided and formed a monolayer network. Third, beginning at about 1 mo and continuing throughout the observation period, cells in the center of the network differentiated extensively and established a colony of spermatogenesis, which expanded laterally by repeating phase two and then three. An average of 19 donor cell-derived colonies developed from 10(6) cells transplanted to the seminiferous tubules of a recipient testis; the number of colonized sites did not change between 1 and 4 mo. However, the length of the colonies increased from 0.73 to 5.78 mm between 1 and 4 mo. These experiments establish the feasibility of studying in a systematic and quantitative manner the pattern and kinetics of the colonization process. Using spermatogonial transplantation as a functional assay, it should be possible to assess the effects of various treatments on stem cells and on recipient seminiferous tubules to provide unique insight into the process of spermatogenesis.  (+info)

Treatment of severe ocular-surface disorders with corneal epithelial stem-cell transplantation. (5/3936)

BACKGROUND: Conditions that destroy the limbal area of the peripheral cornea, such as the Stevens-Johnson syndrome, ocular pemphigoid, and chemical and thermal injuries, can deplete stem cells of the corneal epithelium. The result is scarring and opacification of the normally clear cornea. Standard corneal transplantation cannot treat this form of functional blindness. METHODS: We performed and evaluated 70 transplantations of corneal epithelial stem cells from cadaveric eyes into 43 eyes of 39 patients with severe ocular-surface disorders and limbal dysfunction. Medical treatment had failed in all patients. The patients had a mean preoperative visual acuity of 0.004 (only being able to count the number of fingers presented by the examiner) in the affected eyes, which satisfies the criteria for legal blindness in most countries. In 28 eyes, we also performed standard corneal transplantation. Stem-cell transplantations were performed as many as four times on 1 eye if the initial results were not satisfactory; 19 eyes had multiple transplantations. Patients were followed for at least one year after transplantation. RESULTS: A mean of 1163 days after stem-cell transplantation, 22 of the 43 eyes (51 percent) had corneal epithelialization; of the 22 eyes, 7 eyes had corneal stromal edema and 15 eyes had clear corneas. Mean visual acuity improved from 0.004 to 0.02 (vision sufficient to distinguish the largest symbol on the visual-acuity chart from a distance of 1 m) (P<0.001). The 15 eyes in which the cornea remained clear had a final mean visual acuity of 0.11 (the ability to distinguish the largest symbol from a distance of 5 m). Complications of the first transplantation included persistent defects in the corneal epithelium in 26 eyes, ocular hypertension in 16 eyes, and rejection of the corneal graft in 13 of 28 eyes. The epithelial defects eventually healed in all but two of the eyes. CONCLUSIONS: Transplantation of corneal epithelial stem cells can restore useful vision in some patients with severe ocular-surface disorders.  (+info)

"Global" cell replacement is feasible via neural stem cell transplantation: evidence from the dysmyelinated shiverer mouse brain. (6/3936)

Many diseases of the central nervous system (CNS), particularly those of genetic, metabolic, or infectious/inflammatory etiology, are characterized by "global" neural degeneration or dysfunction. Therapy might require widespread neural cell replacement, a challenge not regarded conventionally as amenable to neural transplantation. Mouse mutants characterized by CNS-wide white matter disease provide ideal models for testing the hypothesis that neural stem cell transplantation might compensate for defective neural cell types in neuropathologies requiring cell replacement throughout the brain. The oligodendrocytes of the dysmyelinated shiverer (shi) mouse are "globally" dysfunctional because they lack myelin basic protein (MBP) essential for effective myelination. Therapy, therefore, requires widespread replacement with MBP-expressing oligodendrocytes. Clonal neural stem cells transplanted at birth-using a simple intracerebroventricular implantation technique-resulted in widespread engraftment throughout the shi brain with repletion of MBP. Accordingly, of the many donor cells that differentiated into oligodendroglia-there appeared to be a shift in the fate of these multipotent cells toward an oligodendroglial fate-a subgroup myelinated up to 52% (mean = approximately 40%) of host neuronal processes with better compacted myelin of a thickness and periodicity more closely approximating normal. A number of recipient animals evinced decrement in their symptomatic tremor. Therefore, "global" neural cell replacement seems feasible for some CNS pathologies if cells with stem-like features are used.  (+info)

The lung in the immunocompromised patient. Infectious complications part 2. (7/3936)

Pulmonary infections decisively contribute to morbidity and mortality in immunocompromised patients. Bacterial, mycobacterial and infections with Pneumocystis carinii have been reviewed in an article in the last issue of Respiration. In this review, viral and fungal pulmonary infections are discussed in HIV-positive patients and in patients treated with high-dose chemotherapy, stem cell or solid-organ transplantation.  (+info)

Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma. (8/3936)

As in other malignancies, peripheral blood progenitor cells (PBPC) have almost completely replaced bone marrow as the source of stem cells for autologous transplantation in multiple myeloma. PBPC collection could be optimized either by reducing contamination by the malignant clone or by increasing hematopoietic quality of the graft. Currently, the most promising technique for purifying the harvest is CD34 cell selection. Several pilot studies have shown the feasibility of this method in MM. However controlled studies are necessary to assess the clinical impact of CD34+ cell selection. In the IFM 94 study, CD34+ selection was optional. There was no significant difference between 50 patients receiving a CD34+ selected graft and 133 patients receiving non-selected PBPC, as regards duration of neutropenia, duration of thrombocytopenia, response rate, EFS or survival. Hematopoietic recovery after transplantation is related to the number of CD34+ cells infused. The optimal regimen for mobilizing the requested CD34+ yield is not yet known. We have completed a randomized study comparing the combination of SCF plus G-CSF and G-CSF alone after priming with cyclophosphamide 4 g/m2. The median number of leukaphereses to reach the target yield of 5x10(6) CD34+ cells/kg was 1 in the SCF group (N=55) versus 2 in the G-CSF group (N=47) (p=0.008). The median number of CD34+ cells collected in the first leukapheresis was 11. 6x10(6) in the SCF group versus 4x10(6) in the G-CSF group (p=0.003). These results are in line with those observed in other trials testing the combination of SCF and G-CSF to improve PBPC collection.  (+info)

These techniques developed by the Stem Cells for Hope Clinics are being applied to implement treatments for a wide range of human degenerative and debilitating conditions, including neurodegenerative diseases, ocular disease and various physiological injuries. Our Global Network of Clinics, who have been treating patients for the last 15 to 18 years, are also involved in ongoing human Stem Cell Research and the Development of new Stem Cell Transplantation Therapy protocols and they are currently successfully treating patients with this Regenerative Medical technology outside of the United States.. Stem Cells for Hope does not have any treatment facilities nor do we treat any patients inside the United States or any other countries where Stem Cell Transplantation Therapy is not approved by the local Government Health Administration.. Please see the Stem Cells for Hope [Medical Forms] for a checklist of medical information that we will require.. Our experienced International Medical and Scientific ...
TY - JOUR. T1 - Regeneration of the central nervous system using endogenous repair mechanisms. AU - Okano, Hideyuki. AU - Sakaguchi, Masanori. AU - Ohki, Koichi. AU - Suzuki, Norihiro. AU - Sawamoto, Kazunobu. PY - 2007/9. Y1 - 2007/9. N2 - Recent advances in developmental and stem cell biology have made regeneration-based therapies feasible as therapeutic strategies for patients with damaged central nervous systems (CNSs), including those with spinal cord injuries, Parkinson disease, or stroke. These strategies can be classified into two approaches: (i) the replenishment of lost neural cells and (ii) the induction of axonal regeneration. The first approach includes the activation of endogenous neural stem cells (NSCs) in the adult CNS and cell transplantation therapy. Endogenous NSCs have been shown to give rise to new neurons after insults, including ischemia, have been sustained; this form of neurogenesis followed by the migration and functional maturation of neuronal cells, as well as the ...
Mainstream of current treatment of liver cirrhosis is liver transplantation, but there are high cost, risk and immune rejection and other issues. Umbilical cord mesenchyma stem cell with self-and directed differentiation capacity can effectively rescue experimental liver failure and contribute to liver regeneration, which suggests the feasibility of stem cell transplantation therapy. In this study, the safety and efficacy of umbilical cord mesenchyma stem cell transplantation through interventional procedures in patients liver cirrhosis will be evaluated ...
Abstract. Results obtained from completed and on-going clinical studies indicate huge therapeutic potential of stem cell-based therapy in the treatment of degenerative, autoimmune and genetic disorders. However, clinical application of stem cells raises numerous ethical and safety concerns.. In this review, we provide an overview of the most important ethical issues in stem cell therapy, as a contribution to the controversial debate about their clinical usage in regenerative and transplantation medicine.. We describe ethical challenges regarding human embryonic stem cell (hESC) research, emphasizing that ethical dilemma involving the destruction of a human embryo is a major factor that may have limited the development of hESC-based clinical therapies. With previous derivation of induced pluripotent stem cells (iPSCs) this problem has been overcome, however current perspectives regarding clinical translation of iPSCs still remain. Unlimited differentiation potential of iPSCs which can be used in ...
Gene replacement strategy and Southern blot analysis of progeny from heterozygous crosses. (a) The wild-type P-selectin allele, the replacement vector, and th
LONDON, Aug. 24, 2020 /PRNewswire/ -- The global stem cell technologies and applications market is estimated to have reached US $17,791.8 million 2020 and ...
Thanks so much to the editors at Vogue Brazil for acknowleging 3LAB Perfect C Serum in their December 2009 issue! The article, on the marvels of apple stem cell technology in skincare, looks at the newest technology and their favorite products that contain it. Thanks so much! ...
By Dr. Kieran OSullivan, University of Limerick, Ireland. And Prof. Peter OSullivan, Curtin University, Australia. The 14-time Grand Slam winner, Rafael Nadals recent struggles to participate at the highest level due to ongoing low back pain (LBP) once again brings the issue of novel therapies offering tantalizing cures to the fore; he is undergoing stem cell therapy (SCT). So it is timely to explore: i) what this therapy potentially offers, ii) the quality of the supporting evidence, iii) its comparison to other needle-based therapies, and iv) what the use of several novel needle-based therapies in the last decade (e.g. stem cell therapy, platelet-rich plasma, dry needling) reveal about attitudes to management of pain in sporting populations.. What is stem cell therapy and why consider it?. Stem cell therapy (SCT) has opened up exciting avenues in health research across many disciplines. Focusing on the role of SCT in LBP, its proposed mechanism of action is regeneration of local spinal ...
However, the FDA is constantly reviewing various other types of stem cell therapy and some of them may receive approval as you are reading this article. A stem cell therapy Highlands Ranch clinic professional suggests that as a basic safety precaution, patients should always ask whether the therapy they propose to undertake has been reviewed by the FDA. Also, ask for clarifications whenever you do not understand something.. Precautions Concerning Travelling Abroad for Stem Cell Therapy. Some patients are lured by promises of more affordable costs for stem cell therapy in other countries. The first thing to remember is that the FDA has no oversight of therapies, treatments and medical procedures performed outside the territory of the USA.. Therefore, patients should always weigh the affordability of the treatment against safety and the possibility to obtain relief in case of malpractice.. ...
Autoimmune Diseases and the Promise of Stem Cell-Based Therapies One of the more perplexing questions in biomedical research is-why does the bodys
Unearth 100+ Medical Centers for Bone Marrow Stem Cell Therapies in Castletown,United Kingdom. Avail Top Stem Cell Therapy Packages at cheap prices.
Taking Organ Transplantation to 2020: A UK strategy has been launched by NHS Blood and Transplant and the four UK health departments. The strategy sets the agenda for increasing organ donation and transplantation rates to world class standards over the next seven years and builds on success in increasing deceased
Youll always face risks when puncturing the skin for any test or procedure. With proper techniques and guidelines infection is exceedingly rare, only about 1 in 1000 are affected at all by infection. Stem cell therapy and growth factor injections are very safe, but still always ensure youre working with the best of doctors and only doing things you understand and are comfortable with. Medicine always comes with risks, the best thing you can do for yourself is research the topic so you know what youre talking about and doing to your body. It is most important to work with a team of skilled medical professionals in stem cell therapy. You can trust NeoGenix Stem Cell Therapy to provide you with a safe and effective procedure.. ...
Stem cell therapies offer great hope to patients with debilitating illnesses and injuries. However, only a limited number of therapies are approved for clinical use. At this event, a panel of experts described the stem cell therapy landscape. The discussants also highlighted the available treatments today, described why even negative clinical data can lead to new interventions, and evaluated recent incidents of unregulated stem cell use harming patients.. This event was part of an annual policy lecture series co-sponsored by the Baker Institute Center for Health and Biosciences and the Texas Heart Institute. Support for the program has been provided by a grant from the George and Mary Josephine Hamman Foundation. Follow @BakerCHB on Twitter and join the conversation online with #BakerStemCell ...
R. Lee Buckler, vice president of business and corporate development at RepliCel Life Sciences Inc., has been an executive in the cell therapy sector since 2000, beginning with Malachite Management in the Stem Cell Technologies group of companies. Most recently he was the managing director of Cell Therapy Group, a firm he formed in 2008 to do business development consulting for companies and organizations working in or interested in the cell therapy sector. His work included deal-targeting, transactions, market intelligence, competitive analyses, strategic assessments and market profile planning for companies ranging from top-tier multinationals to start-ups. Buckler served six years as executive director of the International Society for Cellular Therapy and just over two years as director of business development for Progenitor Cell Therapy. Buckler has a bachelors degree in education, and a law degree. He is on the editorial advisory boards of the journalRegenerative Medicine and the ...
This first systematic evaluation of randomized controlled trials utilizing PMR plans for weight management suggests that these types of interventions can safely and effectively produce significant sustainable weight loss and improve weight-related risk factors of disease.
Find regenerative approach treatment copd. Mississsippi Stem Cell Therapy Center promotes stem cell therapy and regenerative medicine.
Are you considering stem cell therapy to help treat your spinal pain? What you should know about stem cell therapy before pursuing this treatment.
Stem cell therapy takes advantage of your own bodys natural healing power. Advanced research has shown that stem cell therapy is highly effective in spine surgery.
Stem Cell Therapy is becoming more popular thanks to positive testimonials from clients who have trailblazed the biotech frontier with IV and stem cell therapy injections.
Learn about the cost of stem cell therapy. This article describes the costs associated with stem cell therapy in popular countries
Get a free review from one of Americas leading stem cell therapy doctors, Dr. John Parks Trowbridge, serving the Houston, Texas area and beyond!
Poor survival and function of transplanted cells in ischemic and inflamed myocardium likely compromises the functional benefit of stem cell-based therapies. We have earlier reported that co-administration of interleukin (IL)−10 and BMPAC enhances cell survival and improves left ventricular (LV) functions after acute myocardial infarction (MI) in mice. We hypothesized that IL-10 regulates microRNA-375 (miR-375) signaling in BMPACs to enhance their survival and function in ischemic myocardium after MI and attenuates left ventricular dysfunction after MI. miR-375 expression is significantly upregulated in BMPACs upon exposure to inflammatory/hypoxic stimulus and also after MI. IL-10 knockout mice display significantly elevated miR-375 levels. We report that ex vivo miR-375 knockdown in BMPAC before transplantation in the ischemic myocardium after MI significantly improve the survival and retention of transplanted BMPACs and also BMPAC-mediated post-infarct repair, neovascularization, and LV ...
A new study describes a new synthetic hybrid molecule that can selectively target and eliminate pluripotent cells and reduce the tumorigenic threat of cell transplantation strategies
HSCI does not enroll any volunteers in clinical trials. Currently, the only stem cell-based treatment that is routinely reviewed and approved by the U.S. Food and Drug Administration (FDA) is hematopoietic (or blood) stem cell transplantation. It is used to treat patients with cancers and disorders that affect the blood and immune system. Stem cell-based therapies for all other conditions are still experimental.
In the collaboration, Plasticell will use its CombiCult technology to screen combinations of molecules provided by GSK to identify and optimise iPSC differentiation protocols.
Researches carried out by Cambridge University showed possibility for same sex reproduction, according to the study published in Cell.
Stem cell regenerative therapies hold great promise for patients suffering from a variety of disorders that are associated with tissue or organ injury. Regeneration relies on tissue or organ-specific stem and progenitor cells, but can also aim at promoting the endogenous repair capacity of the body. Mesenchymal stromal cells (MSC) are undergoing clinical testing in a variety of clinical conditions aiming at repair through direct or indirect mechanisms. Their ability to form bone or cartilage is used to directly repair these tissues. In other conditions their regenerative effects are based on endogenous repair through their anti-inflammatory properties. The latter mechanism is important in the treatment of acute Graft-versus-Host Disease (GvHD). We have been involved in the clinical development from the beginning and we have shown the therapeutic potential. However, no results of controlled randomized phase 3 studies have been published to date, thereby hampering safety and efficacy ...
Mesoblast shares up two per cent on evidence its stem cell therapy can reduce deaths in children with a complication from bone marrow transplants.
Question - Have diabetes. Is there any operation or stem cell therapy for it?. Ask a Doctor about Kidney transplantation, Ask a Diabetologist
Regenerative medicine researchers successfully attempted stem cell therapy to repair damaged heart muscle in non-human primates.. ...
Learn more about stem cell therapy and regenerative medicine at Spectrum Health Medical Clinic. Find answers to help you improve your life today and live pain free.
Stem cell therapy in Miami have a huge healing potential and have became one of the most popular regenerative medicine treatments in recent years.
A new device that can rapidly concentrate and extract young cells from irrigation fluid used during orthopaedic surgery holds promise for improving the delivery of stem cell therapy in cases of non-healing fractures. UC Davis surgeons plan to launch a proof-of-concept clinical trial to test the safety and efficacy of the device in the coming months.
Engineering Stem Cell Therapies for Heart Repair on Wyss Institute | No therapy currently available can reduce the size of an established scar on the heart.
Scientists who investigated a case of stem cell therapy to treat kidney disease are warning of a new type of complication not seen before, the development of blood vessel and bone marrow masses, the long term effects of which are unknown.
New research has opened the possibility of a new, less invasive lung surgery. This could be the best solution to COPD and similar lung diseases. Find out if stem cell therapy is an effective treatment option for you and your lung disease!
Phase 1 study of stem cell therapy for multiple sclerosis finds no safety issues or signs of disease activation - plus enticing hints of benefits to be explored in phase 2 testing.
Autism is known as the complex brain disorder. This disorder can cause some problems such as the difficulty in communication which can lead to impaired social interactions. In addition, this kind of disorder can cause the acts of obsessive repetition or routine.. The general problem which most of children with autism face is hypoxia. This problem is mainly caused by the condition in which the brain is lack of oxygen. It can cause the immune system not to work appropriately as those with sufficient oxygen.. There are several treatments that are innovative as well as alternative therapies introduced and used over the years ...
Principios fundamentales de la Terapia Celular aplicada al miocardio/Essential concepts of Stem Cell Therapy applied to myocardium ...
The first major concern about the safety and efficacy of stem cell therapy depends on where and by whom the treatments are being performed.
Stem cell therapy is a very important breakthrough in the field of healthcare in India. It has shown remarkable results in various medical conditions.
Dr. Megan Strauchman of the Natural Wellness & Pain Relief Center is among the first physicians in Genesee County to offer stem cell therapy to patients.
Stem cell therapy might provide a remedy for acquired immunodeficiency syndrome (AIDS) after it was used on an HIV patient in Germany, the first person known to have been cured of the disease, a Department of Health (DOH) official said Tuesday.
Dr. Bruce Ruben & Encompass Healthcare & Wound Medicine in West Bloomfield is Michigans #1 infection & wound care facility for stem cell therapy.
The Power That Created The Body Is The Power That Heals The Body Stem Cell Therapy is offering alternatives and hope to many patients who suffer from chronic
AIIMS-Patna achieved a major feat on Wednesday by performing first stem cell therapy in Bihar. A very rare experiment done in select hospitals of the count
AIIMS-Patna achieved a major feat on Wednesday by performing first stem cell therapy in Bihar. A very rare experiment done in select hospitals of the count
Give mom something unique this year: stem cell therapy! These treatments make great presents for mom, allowing her to be free of pain. Learn more-305-598-7777.
According to Roots Analysis, With over 280 therapies under evaluation, the stem cell therapy market is estimated to be worth USD 8.5 Billion by 2030…
... (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. doi:10.1634/stemcells.19-2- ... Stem cell transplantation was pioneered using bone-marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research ... See also: List of conditions treated with hematopoietic stem cell transplantation. Indications[edit]. Indications for stem cell ...
Stem cell transplantation[edit]. In 2007, Timothy Ray Brown,[12] a 40-year-old HIV-positive man, also known as "the Berlin ... Stem cell based gene therapy[edit]. In the past 7 years, scientists have been using different approaches of stem cell based ... One study done in 2011 achieves successful CD4+ T-cell reconstitution as a result of CCR5Δ32/Δ32 stem cell transplantation at ... Schneider, Thomas (2011-03-10). "Evidence for the cure of HIV infection by CCR532/32 stem cell transplantation". Blood. 117 (10 ...
Robert J. Soiffer (17 November 2008). Hematopoietic Stem Cell Transplantation. Springer. ISBN 978-1-934115-05-3. Retrieved 23 ... Haematopoietic stem cell transplant remains the only curative treatment for CMML. However, due to the late age of onset and ... as well as abnormal looking cells (dysplasia) in at least one type of blood cell. CMML shows characteristics of a ... In adults, blood cells are formed in the bone marrow, by a process that is known as haematopoiesis. In CMML, there are ...
"Stem cell transplantation for neuroblastoma". Bone Marrow Transplantation. 41 (2): 159-65. doi:10.1038/sj.bmt.1705929. PMC ... "Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma". Biology of Blood and Marrow Transplantation. ... Observation, surgery, radiation, chemotherapy, stem cell transplantation[1]. Prognosis. US five-year survival ~95% (, 1 year ... A haploidentical stem cell transplant, that is, donor cells derived from parents, is being studied in those with refractory or ...
June 2008). "Stem cell transplantation for primary immunodeficiencies". Bone Marrow Transplant. 41 Suppl 2: S83-6. doi:10.1038/ ... cell responses to mitogens and allogeneic cells, cytokine production by cells Tests for B cell function: antibodies to routine ... Virus-specific T-Lymphocytes (VST) therapy is used for patients who have received hematopoietic stem cell transplantation that ... natural killer cells and monocytes (CD15+), as well as activation markers (HLA-DR, CD25, CD80 (B cells). Tests for T cell ...
Stem cell transplantation is being studied and has shown promising results in certain cases.[50] ... Blood cells are produced in the bone marrow by stem cells that reside there. Aplastic anaemia causes a deficiency of all blood ... A test taking measurements on maturity levels, count, and size of blood cells.[28][37] Targeted cells include: red blood cells ... "Haematopoietic stem cell transplantation for autoimmune diseases". Nature Reviews. Rheumatology. 13 (4): 244-256. doi:10.1038/ ...
"Intraspinal stem cell transplantation for amyotrophic lateral sclerosis". Annals of Neurology. 79 (3): 342-53. doi:10.1002/ana. ... One 2016 review of stem-cell therapy trials found tentative evidence that intraspinal stem cell implantation was relatively ... Prion-like propagation of misfolded proteins from cell to cell may explain why ALS starts in one area and spreads to others.[27 ... Induced pluripotent stem cells (iPSCs) can be used to convert skin fibroblasts into motor neurons.[11] It is now possible to ...
Hematopoietic stem cell transplantation (HSCT) with high intensity conditioning protocol has been performed in a few cases with ... There is a limited but encouraging therapeutic experience of hematopoietic stem cell transplantation for SPS. ... "Autologous Stem Cell Transplantation for Stiff Person Syndrome". JAMA Neurology. 71 (10): 1296-9. doi:10.1001/jamaneurol. ... "Autologous haematopoietic stem cell transplantation for neurological diseases". J Neurol Neurosurg Psychiatry. 89 (2): 147-155 ...
Fertility Issues Following Hematopoietic Stem Cell Transplantation. Expert Rev Hematol. 2013, 6 (4): 375-388. PMID 23991924. ... Fertility Issues Following Hematopoietic Stem Cell Transplantation. Expert Rev Hematol. 2013, 6 (4): 375-388. PMID 23991924. ... Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet. 2001, 358 (9278): 271 ...
Successful photoreceptor transplantation, MIT Technology Review, November 2006. How stem cells might restore sight Technology ... Cells. *Photoreceptor cells (Cone cell, Rod cell) → (Horizontal cell) → Bipolar cell → (Amacrine cell) → Retina ganglion cell ( ... Parasol cell, Bistratified cell, Giant retina ganglion cells, Photosensitive ganglion cell) → Diencephalon: P cell, M cell, K ... Ganglion cell axons travelling towards the optic nerve 4. Ganglion cell layer (GCL). Ganglion cell bodies (and some displaced ...
2004).Effective treatment of alpha-mannosidosis by allogeneic hematopoietic stem cell transplantation. J Pediatr, 144:569-573. ... Hematopoietic stem cell transplantation (HSCT) can be a treatment option for some patients, however the risk-benefit profile is ... 1987). "Bone marrow transplantation in the treatment of alpha-mannosidosis". Disease in Childhood. 62 (10): 1044-1049. doi: ... Identification of disease-causing mutations is achieved using DNA from peripheral blood cells, by polymerase chain reaction ( ...
March 10, 2011). "Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation". Blood. 117 (10).. ... "Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation". N Engl J Med. 360 (7): 692-698. doi:10.1056/ ... "Eradication of HIV by transplantation of CCR5-deficient hematopoietic stem cells". The Scientific World Journal. 11: 1068-1076 ... "Man appears free of HIV after stem cell transplant". CNN. 2009-02-11. Retrieved 2009-03-08.. ...
Bone marrow and stem cell transplantation are effective for all types of cytopenias. However, when a compatible donor cannot be ... Epoetin alpha - a synthetic erythropoietin that stimulates stem cells to produce red blood cells. ... Pancytopenia - When all three types of blood cells; red blood cells, white blood cells, and platelets, are all deficient. This ... Cytopenia is a reduction in the number of mature blood cells.[1] It is common in cancer patients being treated with radiation ...
The Neuroethics of Intracerebral Stem Cell Transplantation and Deep Brain Stimulation. Verlag; 2010. ISBN 978-3-8376-1433-6. ... he summarised Moniz's rationale for the procedure as based on the fact that while no physical abnormality of cerebral cell ... "fixation of certain patterns of relationship among various groups of cells" and that this resulted in obsessions, delusions and ...
Westgren M, Götherström c (3 June 2015). "Stem cell transplantation before birth - a realistic option for treatment of ... abnormal cell to cell interactions, abnormal cell-matrix interactions, a compromised cell matrix structure, and disturbances ... Surgery for basilar impressions can be carried out if pressure being exerted on the spinal cord and brain stem is causing ...
"Hematopoietic stem cell transplantation for X-linked thrombocytopenia with mutations in the WAS gene." Journal of clinical ... Recent research has suggested that hematopoietic stem cell transplantation may be a treatment option for patients with XLT ... Platelets are cell fragments in the blood that aid in clotting. Platelets are produced in the bone marrow. Normal platelet ... Anemia is a condition in which there is an insufficient number of red blood cells to carry adequate levels of oxygen to the ...
... stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation ... preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells.. „Stem Cells ... Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?. „Proc ... Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. „J Clin Oncol". 28 (23), s ...
The Lancet Editors (2016). "Expression of concern-Tracheobronchial transplantation with a stem-cell-seeded bioartificial ... "Boy's windpipe replaced in pioneering stem cell operation". The Guardian.. *^ a b c d e f g h i j Kremer, William (September 10 ... "The Transplantation Society.. *^ a b c d e f g h i j k "The Macchiarini Case (English summary)" (PDF). Stockholms läns ... Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: A proof-of-concept study". The Lancet. ...
Allogeneic hematopoietic stem cell transplantation should be considered in fit patients with suitable available donor, as long ... July 2008). "Allogeneic Hematopoietic Stem-Cell Transplantation for Myeloid Sarcoma: A Retrospective Study From the SFGM-TC". J ... those whose myeloblasts express T-cell surface markers, CD13, or CD14 those with high peripheral white blood cell counts ... Meningeal leukemia, or invasion of the subarachnoid space by leukemic cells, is usually considered distinct from chloroma, ...
Treatment of the epidermolysis bullosa by transplantation of laminin5 modified stem cells ... "Long-shot stem-cell treatment gives two brothers a future". Star Tribune. Retrieved 2008-07-22.. ... "Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources". ... "Bone Marrow Transplantation. 31 (12): 1704105. doi:10.1038/sj.bmt.1704105.. *^ Fine, Jo-David; Manes, Becky; Frangoul, Haydar ( ...
"Dry eye after haematopoietic stem cell transplantation". The British Journal of Ophthalmology. 83 (10): 1125-30. doi:10.1136/ ... Since iron is a major component of bacterial cell walls, removal of iron breaks down the cell wall, which in turn breaks down ... Secretory cells are found in a group, or acinus (plural, acini). Each acinus is located at the terminal part of the gland ... Graft versus host disease after allogeneic bone marrow transplantation may manifest as dry mouth and many small mucoceles.[36] ...
The Cancer Center's Adult Blood and Marrow Stem Cell Transplantation Program is one of the top eight in the United States.[6] ...
Prophylactic cranial and stem cell transplantation for high-risk patients.[73]. Acute myeloid leukemia (AML). Induction with ... Hemato oncology: focuses on cancers of blood and stem cell transplantation. *Preventive oncology: focuses on epidemiology & ... Stem cell transplantation for high-risk patients.[74]. Chronic lymphocytic leukemia (CLL): Chemo-immunotherapy (FCR or BR ... Chemo-immunotherapy (R-CHOP) for B cell lymphomas, and chemotherapy (CHOP) for T cell lymphomas.[72]. Blood cancerEdit. ...
"Stem cells, cell transplantation and liver repopulation". Marion Bessin Liver Research Center, Division of Hepatology, ... "Epimorphin regulates bile duct formation via effects on mitosis orientation in rat liver epithelial stem-like cells". Stem Cell ... "Hepatic progenitor cells, stem cells, and AFP expression in models of liver injury". Division of Radiooncology, Deutsches ... "Hepatic stem cells: a review". Department of Anatomical Pathology, University of Cape Town; Vessey CJ, de la Hall PM. Diakses ...
There are also reports that stem cell transplantation is successful in a limited number of participants[16] ... There have been numerous studies that have stated that bone marrow transplantation is successful.[17] This is a recently new ... If a patient has a life-threatening infectious complication then bone marrow transplantation is no longer relevant for them. ... "Allogeneic bone marrow transplantation in a 7-year-old girl with congenital erythropoietic porphyria: a treatment dilemma". ...
Grigg A, Gibson R, Bardy P, Szer J (1996). "Acute portal vein thrombosis after autologous stem cell transplantation". Bone ... Busulfan is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Its chemical ... As an adjunct therapy with cyclophosphamide for conditioning prior to bone marrow transplantation in adults and children ,12 kg ... Because the intrastrand DNA crosslinks cannot be repaired by cellular machinery, the cell undergoes apoptosis.[8] ...
"Quantitative Magnetic Particle Imaging Monitors the Transplantation, Biodistribution, and Clearance of Stem Cells In Vivo" ... Imaging can be used to improve the success of stem cell therapy by following the movement of these cells in the body.[3] The ... Cell tracking[edit]. By tagging therapeutic cells with iron oxide nanoparticles, MPI allows them to tracked throughout the body ... "Magnetic Particle Imaging tracks the long-term fate of in vivo neural cell implants with high image contrast". Scientific ...
... differential admixture and its potential impact on hematopoietic stem cell transplantation". Bone Marrow Research. 2012: 1-13. ... "Cell. 162 (5): 1051-65. doi:10.1016/j.cell.2015.07.048. PMC 4556133. PMID 26300125.. ... doi:10.1016/j.cell.2007.11.037. PMID 18160035.. *^ Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. ( ... CCR5 gene is absent on the surface of cell due to mutation. Without CCR5 gene on the surface, there is nothing for HIV viruses ...
T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer ... T Cells to protect tumour cells. Nature Communications. March 2018, 9 (1): 948. PMC 5838096. PMID 29507342. doi:10.1038/s41467- ... 细胞毒性T细胞(CTLs, killer T cells)负责杀伤被病毒感染的细胞和癌细胞,在对器官移植的免疫排斥中也有参与。其特点在于细胞表面的CD8蛋白质。它通过识别所有有核细胞表
... allowing a new population of healthy B cells to develop from lymphoid stem cells. ... It is also used as induction therapy in highly sensitized patients going for kidney transplantation. The use of rituximab has ... cells in destroying these B cells. When an NK cell latched onto the cap, it had an 80% success rate at killing the cell. In ... The antibody binds to the cell surface protein CD20. CD20 is widely expressed on B cells, from early pre-B cells to later in ...
Wu DC, Boyd AS, Wood KJ (2007). "Embryonic stem cell transplantation: potential applicability in cell replacement therapy and ... Lindvall O (2003). "Stem cells for cell therapy in Parkinson's disease". Pharmacol Res 47 (4): 279-87. PMID 12644384. ... Gahrton G, Björkstrand B (2000). "Progress in haematopoietic stem cell transplantation for multiple myeloma". J Intern Med 248 ... "Researchers find new method for turning adult cells into stem cells". Amherst Daily News. Canadian Press. 2009-01-03. Vaadatud ...
Further in the future, stem cell biotechnology may also make this possible, with no need for anti-rejection drugs. ... Fageeh, W.; Raffa, H.; Jabbad, H.; Marzouki, A. (2002). "Transplantation of the human uterus". International Journal of ... See also: Transgender pregnancy, Uterus transplantation § Application on transgender women, and Male pregnancy § Humans ...
In particular, mesenchymal stem cells have been shown in animal models to regenerate cartilage. Recently, there have been ... called matrix-associated autologous chondrocyte transplantation (MACT), grows the patient's cells in a 3D matrix of resorbable ... For years, the concept of harvesting stem cells and re-implanting them into one's own body to regenerate organs and tissues has ... An advantage to this approach is that a person's own stem cells are used, avoiding tissue rejection by the patient's immune ...
... platelet activation in vascular disease and stem cell transplantation in cancer patients. As an endocrinologist he has an ... The staging and prognostic value of subset markers on CD8 cells in HIV disease. In Janossy G, Autran B. Miedema F (eds): ... His interest in immunology has led to publications in HIV disease, cellular activation and natural killer cell function, tumor ... Enumeration of CD4+ T-cells in the peripheral blood of HIV-infected patients: interlaboratory study of the FACSCount system. ...
"Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell ... Stopping smoking, respiratory rehabilitation, lung transplantation[2]. Medication. Vaccinations, inhaled bronchodilators and ... "Harnessing the potential of lung stem cells for regenerative medicine". The International Journal of Biochemistry & Cell ... Several new long-acting agents are under development.[2] Treatment with stem cells is under study.[201] While there is ...
Updated: 16 December 2013 Why Perform a Stem Cell Transplant?. *↑ Bone Marrow Transplantation and Peripheral Blood Stem Cell ... "Journal of Stem Cells and Regenerative Medicine.. *↑ "Index of CD34+ Cells and Mononuclear Cells in the Bone Marrow of Spinal ... name="nih",Stem Cell Basics: What are the potential uses of human stem cells and the obstacles that must be overcome before ... Making human embryonic stem cells». The Economist. 2007-11-22.. *↑ Ian Murnaghan for Explore Stem Cells. ...
For a long time, the most efficient approach had been to use bone marrow graft, or hematopoietic stem cell transplantation. ... Because of all these reasons, bone marrow grafts or hematopoietic stem cell transplantation have seen a decrease in their ... long term follow-up on patients undergone to hematopoietic stem cell transplantation, Minerva Pediatr. 2013 Oct;65(5):487-96. ... The matrix surrounds the cells of the body in an organized meshwork and functions as the glue that holds the cells of the body ...
... surgical techniques are used to remove an invasive malignancy that extends to the clitoris. Standard surgical procedures are followed in these cases. This includes evaluation and biopsy. Other factors that will affect the technique selected are age, other existing medical conditions, and obesity. Other considerations are the probability of extended hospital care and the development of infection at the surgical site.[3] The surgery proceeds with the use of general anesthesia, and prior to the vulvectomy/clitoridectomy an inguinal lymphyadenectomy is first done. The extent of the surgical site extends one to two centimeters beyond the boundaries of malignancy. Superficial lymph nodes may also need to be removed. If the malignancy is present in muscular tissue in the region, it is also removed. In some cases, the surgeon is able to preserve the clitoris though the malignancy may be extensive. The cancerous tissue is removed and the incision is closed.[3] Post operative care may ...
Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proceedings of the ... KK Ballen, F Verter and J Kurtzberg Umbilical cord blood donation: public or private? Bone Marrow Transplantation (2015), 1-8 ... Increased migration of cord blood-derived CD34+ cells, as compared to bone marrow and mobilized peripheral blood CD34+ cells ...
Transplantation of stem cells is also known to cause toxicity and graft-versus-host disease (GVHD). Apoptotic cells have been ... Side effects of cell transplantationEdit. A study has shown that cell transplantation may cause an increase in body temperature ... Pessach I, Shimoni A, Nagler A (November 2012). "Apoptotic cells in allogeneic hematopoietic stem cell transplantations: " ... Stem cell transplantation has been identified as another possible therapy for axonal regeneration in the central nervous system ...
The cause is usually a mutation that occurred in an early stem cell that gave rise to all or part of the gametes. ... The earliest examples of this involved transplantation experiments (technically creating chimeras) where cells from a blastula ... The 46/47 annotation indicates that the XY cells have the normal number of 46 total chromosomes, and the XXY cells have a total ... After further rounds of replication, this cell would result in a patch, or "clone" of cells mutant for the allele being studied ...
Hyman B, Van Hoesen GW, Damasio A, Barnes C. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation" ... suggesting that brain stem nuclei are critical platforms as well.[10] He regards feelings as the necessary foundation of ... Hyman B, Van Hoesen GW, Damasio A, Barnes C (1984). "Alzheimer's disease: Cell-specific pathology isolates the hippocampal ... suggesting that brain stem structures play a basic role in the feeling process.[9] ...
május 1.). „Transplantation of Living Nuclei From Blastula Cells into Enucleated Frogs' Eggs". Proc Natl Acad Sci U S A. 38 (5 ... Cloning and Stem Cell Discoveries Earn Nobel in Medicine (New York Times, 2012. október 8.) .mw-parser-output .nyelvcimke{font- ... 2006) „From Nuclear Transfer to Nuclear Reprogramming: The Reversal of Cell Differentiation". Annual Review of Cell and ... 2008) „Sir John Gurdon: Godfather of cloning". The Journal of Cell Biology 181 (2), 178-179. o. DOI:10.1083/jcb.1812pi. PMID ...
Roskams T (June 2006). "Liver stem cells and their implication in hepatocellular and cholangiocarcinoma". Oncogene. 25 (27): ... Surgical resection, chemotherapy, radiation therapy, stenting procedures, liver transplantation[1]. Prognosis. Generally poor[5 ... has suggested that the initial transformed cell that generates the primary tumor may arise from a pluripotent hepatic stem cell ... "Possible stem cell origin of human cholangiocarcinoma". World Journal of Gastroenterology. 10 (22): 3374-6. doi:10.3748/wjg.v10 ...
... successfully treated with high-dose ampicillin-sulbactam in a pediatric patient after hematopoietic stem cell transplantation ... AS allows the microbe to bind to target cells and it facilitates the transfer of genetic material between cells.[4] ...
2018-10-16: Stem Cell Research (journal). *2018-10-16: Stem Cells (journal) ... 2019-03-19: Cell Transplantation. *2019-03-14: Journal of Speech, Language, and Hearing Research ...
... a stem cell-the blood-forming stem cell-which set the stage for all current research on adult and embryonic stem cells.[40] ... For the development of liver transplantation, which has restored normal life to thousands of patients with end-stage liver ... Discoveries concerning nuclear reprogramming, the process that instructs specialized adult cells to form early stem cells- ... For the discovery of the pathway by which cells from humans and most animals sense and adapt to changes in oxygen availability ...
It has been found that men with a higher percentage of hematopoietic stem cells in blood lacking the Y chromosome (and perhaps ... Transplantation. 17 (4): 346-354. doi:10.1097/00007890-197404000-00003. ISSN 0041-1337. PMID 4823382. S2CID 35983351.. ... Graves JA (March 2006). "Sex chromosome specialization and degeneration in mammals". Cell. 124 (5): 901-14. doi:10.1016/j.cell. ... Men can lose the Y chromosome in a subset of cells, which is called the mosaic loss of chromosome Y (LOY). This post-zygotic ...
Lei M, Chuong CM (2016). "STEM CELLS. Aging, alopecia, and stem cells". Science. 351 (6273): 559-60. Bibcode:2016Sci...351.. ... Hair transplantation is usually carried out under local anaesthetic. A surgeon will move healthy hair from the back and sides ... hair follicle renewal is maintained by the stem cells associated with each follicle. Aging of the hair follicle appears to be ... "Hair follicle aging is driven by transepidermal elimination of stem cells via COL17A1 proteolysis". Science. 351 (6273): ...
Human red blood cells are produced through a process named erythropoiesis, developing from committed stem cells to mature red ... The blood type needs to be determined to prepare for a blood transfusion or an organ transplantation. ... Red blood cells, also known as RBCs, red cells,[1] red blood corpuscles, haematids, erythroid cells or erythrocytes (from Greek ... In 2008 it was reported that human embryonic stem cells had been successfully coaxed into becoming red blood cells in the lab. ...
... derived from bone marrow resident hematopoietic stem cells). Developing T cells are referred to as thymocytes and are of ... The newly formed organ resembled a normal thymus histologically and molecularly, and upon transplantation it was able to ... Stromal cells include epithelial cells of the thymic cortex and medulla, and dendritic cells. The thymus provides an inductive ... Second, the T cell undergoes "Negative Selection" by interacting with thymic dendritic cells, whereby T cells with high ...
Chemotherapy, stem cell transplantation, radiation therapy, targeted therapy[1]. Prognosis. Children: 90% five-year survival ... T cell or pre-B cell Large and heterogeneous (varied) cells ALL - L3 B cell Large and varied cells with vacuoles Mature B-cell ... Chemotherapies or stem cell transplantations may require a platelet transfusion to prevent bleeding.[58][59] Moreover, patients ... about the therapeutic effect of mesenchymal stromal cells to treat graft-versus-host diseases after a stem cell transplantation ...
Stem cell treatment[edit]. Autologous stem-cell transplantation using mesenchymal stem cells (MSCs) has been used to improve ... MSCs are multipotent stem cells, meaning they can differentiate into multiple cell types. In the case of mesenchymal stem cells ... these cell types include osteoblasts (bone cells), adipocytes (fat cells), and chondrocytes (cartilage cells). Ligament tissue ... Ligament cells differ in size, respond to different cues in the cell environment, and express different cell surface markers, ...
Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. doi:10.1634/stemcells.19-2- ... Stem cell transplantation was pioneered using bone-marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research ... See also: List of conditions treated with hematopoietic stem cell transplantation. Indications[edit]. Indications for stem cell ...
Current research in Stem Cell Transplantation (SCT) focuses on improving transplant outcome through immune manipulations using ...
This article explores the process of transplantation, how to choose a donor, and the risks involved with such a procedure. Read ... Hematopoietic stem cell transplantation is approved for use in treating some types of cancer and is an experimental treatment ... While the therapy is a form of stem cell transplantation, the stem cells are not the main part of the story. In fact, the key ... Popular in: Stem Cell Research. * What are stem cells, and what do they do? ...
Hematopoietic stem cell transplantation (HSCT) has been used as curative treatment in both children and adults for hematologic ... Graft-versus-host disease Stem cell transplantation Skin cancer Squamous cell cancer Basal cell cancer Melanoma Autoimmune ... Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an ... Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617-24.PubMedCentralCrossRefPubMedGoogle ...
A combination of drugs increases the number of blood stem cells released by bone marrow into circulation and could help ... Improving Blood Stem Cell Transplantation. Research Update March 13, 2013. A recent study conducted in mice, baboons, and human ... Meloxicam in combination with G-CSF may improve the success rates of blood stem cell transplantation by making it easier to ... stem cells (HSCs) and their descendent hematopoietic progenitor cells (HPCs) entering the circulation from the bone marrow, ...
Stem Cell Transplantation in minutes with SmartDraw. SmartDraw includes 1000s of professional healthcare and anatomy chart ... Stem Cell Transplantation. donor. stem cells from. peripheral blood. Allogeneic stem cell transplantation. Stem Cell come form ... Bone marrow transplantation. Umbilical cord blood transplantation. Autologous stem cell transplantation. Syngeneic stem cell ... Leukemia - Stem Cell Transplantation. Create healthcare diagrams like this example called Leukemia - Stem Cell Transplantation ...
Early trial results show autologous hematopoietic stem cell transplantation has helped patients with multiple sclerosis walk ... Could stem cell transplantation yield a cure for MS?. Written by Honor Whiteman. on January 27, 2016 ... In the documentary, she revealed how she started to see amazing results within days of undergoing stem cell transplantation. ... HSCs are adult stem cells that are made in bone marrow. They have the ability to renew themselves and make different cells ...
Studies have shown that stem cell transplantation could aid in the restoration of brain function in patients with medical ... Optimizing stem cell transplantation. BioPhotonics. Aug 2007 Researchers use labeling technique and MRI to track cells in vivo ... Using MRI, they tracked the stem cells in vivo after transplantation into the rodent brain. In the uninjured neonatal brain, in ... Studies have shown that stem cell transplantation could aid in the restoration of brain function in patients with medical ...
Its important to weigh the risks and benefits of stem cell transplantation with your doctor as you consider your treatment ... Allogeneic stem cell transplantation (infusion of donor stem cells into a patient) is the best-documented curative treatment ... Allogeneic Stem Cell Transplantation. *Download or order The Leukemia & Lymphoma Societys free booklet, Blood and Marrow Stem ... On the one hand, transplantation has a proven curative track record for some CML patients. On the other hand, the TKIs may be ...
Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation ... stem cell hematopoietic stem cell transplantation immunotherapy leukemia lymphoma morbidity mortality stem cell stem cell ... Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell ... Developments in Immuno-, Molecular, and Cell Biology: Implications for Clinical Stem Cell Transplantation. * Front Matter Pages ...
Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to your body after ... Patients Disease Information Treatment Types of Treatment Stem Cell Transplantation Allogeneic Stem Cell Transplantation ... Because of the smaller number of stem cells, cord blood stem cell transplants engraft more slowly than stem cells from marrow ... Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to your body after ...
Meerim Park and Jong Jin Seo, "Role of HLA in Hematopoietic Stem Cell Transplantation," Bone Marrow Research, vol. 2012, ... Role of HLA in Hematopoietic Stem Cell Transplantation. Meerim Park1 and Jong Jin Seo2 ...
H. J. Pegram, D. S. Ritchie, M. J. Smyth et al., "Alloreactive natural killer cells in hematopoietic stem cell transplantation ... "The role of anti-HLA antibodies in hematopoietic stem cell transplantation," Biology of Blood and Marrow Transplantation, vol. ... M. Park, K. N. Koh, B. E. Kim et al., "The impact of HLA matching on unrelated donor hematopoietic stem cell transplantation in ... D. Gallardo, S. Brunet, A. Torres et al., "HLA-DPB1 mismatch in HLA-A-B-DRB1 identical sibling donor stem cell transplantation ...
... To Reflect Significant Incremental Opportunity During 2018-2026 By ... Application of Stem Cells in Cell Therapy 3.1 Stem Cells Ability to Differentiate 3.1.1 Totipotent Stem Cells 3.1.2 Pluripotent ... Necessity for Cell Therapy Treatment 2.1 Emergence of Stem Cell Research 2.2 Benefits of Using the Stem Cell for Research and ... propelling growth of the hematopoietic stem cell transplantation (HSCT) market. Increasing awareness about stem cell therapies ...
We used an ex vivo hematopoietic stem and progenitor cell/EC (HSPC/EC) coculture system as well as in vivo EC infusions ... changes in the hematopoietic compartment are primarily attributed to cell-intrinsic alterations in hematopoietic stem cells ( ... Here, we determined that aging of endothelial cells (ECs), a critical component of the BM microenvironment, was sufficient to ...
Stem-cell based therapies to strengthen the heart muscle and treat other diseases are beginning to show promise in human ... Experimental noninvasive tool assesses efficacy of stem cell transplantation. *Download PDF Copy ... Progenitor Cells, Receptor, Research, Stem Cells, Surgery, Transplant, Trauma ... Stem-cell based therapies to strengthen the heart muscle and treat other diseases are beginning to show promise in human ...
Haematopoietic stem cell transplantation has been proposed as treatment for mitochondrial neurogastrointestinal ... Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy Brain. 2015 Oct; ... 24 24 Stem Cell Transplantation Unit, Internal Medicine Department, Ribeirao Preto School of Medicine, Sao Paulo University, ... Allogeneic haematopoietic stem cell transplantation should be considered for selected patients with an optimal donor. ...
Researchers analyzed biomarkers secreted from transplanted human stem cells in the recipient blood of a rodent model of heart ... Experimental Noninvasive Tool Monitors Effectiveness of Stem Cell Transplantation. University of Maryland School of Medicine ... All Journal News Cardiovascular Health Cell Biology Heart Disease Stem Cells Embargoed Feed - hidden ... describes how a liquid biopsy may show the activity and effectiveness of stem cell transplantation in a receptor organ. ...
... autologous stem cell transplantation (ASCT) remains the standard of care for young patients with newly diagnosed multiple ... Who is most suited to undergo ASCT? Is there an age threshold that should not be surpassed? Should transplantation be embarked ... What is the role of tandem transplantation in the era of novel agents and where do patient-specific cytogenetics come into the ... The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia ...
Therefore, the aim of this study was to assess the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) ... These data suggest that better control of GS prior to allo-HSCT is crucial to improve the outcome of transplantation for those ... A total of 44 patients (8.7%) had GS before transplantation. Patients with GS achieved comparable survival to those without GS ... Better disease control before allogeneic stem cell transplantation is crucial to improve the outcomes of transplantation for ...
... stem cell transplant patients and their families receive care from a closely knit multidisciplinary team of clinicians. ... Blood and Bone Marrow Stem Cell Transplantation Team. Michael R. Bishop, MD Director, Hematopoietic Stem Cell Transplantation ... Lucy Godley on Stem Cell Transplant Lucy Godley, MD, PhD, talks about what stem cell transplants are like for the patient ... Home , Specialties , Cancer Care , Information by Type of Cancer , Blood and Bone Marrow Stem Cell Transplantation , ...
Stem Cell Transplantation as a Strategy for HIV Cure. SCT has been investigated as a strategy to treat HIV infection since the ... Hematopoietic Stem Cell Transplantation as a Therapy for Hematologic Malignancies in HIV-Infected Persons. Before the ... Hematopoietic stem cell transplantation (SCT) is emerging as a safe and effective therapy for HIV-infected persons with ... infected individuals are at increased risk for a range of hematologic cancers for which stem cell transplantation (SCT) is ...
Before transplantation, patients receive intensive myeloablative chemoradiotherapy followed by stem cell ... More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each year for the treatment of lymphoma, ... Hematopoietic stem cell transplantation Eleftheria Hatzimichael1, Mark Tuthill21Department of Haematology, Medical School of ... transplantation procedures, and potential complications.. Keywords: hematopoietic stem cell transplantation, complications. ...
Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review.. Ariza-Heredia EJ1, Nesher L, Chemaly RF ... Cytomegalovirus (CMV) infection remains a significant complication after hematopoietic stem cell transplantation (HSCT) and may ... have a deleterious impact on the overall outcome after transplantation. In addition to the direct effects of CMV infection, ...
A study published by Cell Press June 19 in Stem Cell Reports reveals that simultaneous transplantation of neural and vascular ... The stem cell-based approach could represent a promising strategy for the treatment of stroke in humans. ... progenitor cells can reduce stroke-related brain damage and improve behavioral recovery in rodents. ... Stem cell-based transplantation approach improves recovery from stroke. Cell Press. Journal. Stem Cell Reports. Keywords. * ...
As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves ... Single versus double autologous stem-cell transplantation for multiple myeloma.. Attal M1, Harousseau JL, Facon T, Guilhot F, ... of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. ... Tandem bone marrow transplantation in multiple myeloma. [N Engl J Med. 2004] ...
Stem Cell Transplantation Fellowship. The Stem Cell Transplantation and Cellular Therapy Department offers specialized training ... Stem Cell Transplantation Department. UT MD Anderson Cancer Center. 1515 Holcombe Blvd., Unit 423. Houston, TX 77030 ... Identify appropriateness of stem cell product therapy, growth factor therapy and transfusion medicine as is relevant to ... Understand principles of apheresis and photopheresis as relevant to stem cell collection and for the treatment of TTP and GVHD ...
Transplanting human embryonic stem cells does not cause harm... ... Research confirms ability of stem cells to repair acute spinal ... In 2005, Keirstead s lab was the first to coax human embryonic stem cells to become highly pure specialized cells known as ... Our biggest safety concern was that in the case of a severe injury, any harm the stem cell-derived treatment could cause would ... The university announced last week that it had received a $10 million gift from Bill and Sue Gross in support of stem cell ...
Mesenchymal Stem Cell Transplantation in MS. Official Title ICMJE Autologous Mesenchymal Stem Cell Transplantation in Multiple ... autologous mesenchymal stem cell A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs ... Mesenchymal Stem Cell Transplantation in MS (CMM-EM). The safety and scientific validity of this study is the responsibility of ... Biological: autologous mesenchymal stem cells A randomized double-blind, crossover study comparing treatment with autologous ...
  • The patient's own stored stem cells are then transfused into his/her bloodstream, where they replace destroyed tissue and resume the patient's normal blood cell production. (
  • For the journal abbreviated Bone Marrow Transplant , see Bone Marrow Transplantation (journal) . (
  • The Worldwide Network for Blood and Marrow Transplantation reported the millionth transplant to have been undertaken in December 2012. (
  • Current research in Stem Cell Transplantation (SCT) focuses on improving transplant outcome through immune manipulations using cell therapy and lymphocyte growth factors. (
  • Nonmelanoma skin cancer in childhood after hematopoietic stem cell transplant: a report of 4 cases. (
  • Meloxicam in combination with G-CSF may improve the success rates of blood stem cell transplantation by making it easier to obtain sufficient numbers of cells for transplant. (
  • The second edition is fully revised and includes new chapters on microbiome, metabolism, kinase targets, micro-RNA and mRNA regulatory mechanisms, signaling pathways in GVHD, innate lymphoid system development, recovery and function in GVHD, genetically engineered T-cell therapies, immune system engagers for GVHD and graft-versus-tumor, and hematopoietic cell transplant for tolerance induction in solid organ grafts. (
  • The immune reaction, or GVHD, is treated by administering drugs to the patient after the transplant that reduce the ability of the donated immune cells to attack and injure the patient's tissues. (
  • One goal of allogeneic stem cell transplant is to cause the T lymphocytes in the donor's blood or marrow to take hold (engraft) and grow in the patient's marrow. (
  • The technique involves treating the stem cells collected for transplant with agents that reduce the number of T lymphocytes. (
  • If the HLA on the donor cells are identical (from identical twins, for example) or similar (such as those from siblings), the transplant is more likely to be successful. (
  • 12 12 Stem Cell Transplant and Cellular Therapy Unit, University Hospital, Siena, Italy. (
  • Lucy Godley, MD, PhD, talks about what stem cell transplants are like for the patient receiving the transplant, potential complications associated with the procedure, and the long-term prognosis after transplant. (
  • Please call our Physician Referral Center at (800) 995-5724 to refer a patient to the Stem Cell Transplant program. (
  • The ability to transplant stem cells allows physicians to use higher doses of chemotherapy Treatment with drugs to stop the growth of rapidly dividing cancer cells, including lymphoma cells. (
  • Compared with a standard allogeneic transplant A procedure in which a patient receives bone marrow or stem cells donated by another person. (
  • To guide you through the transplantation process, LRF has developed a Transplant Journey Checklist to help keep you on track during this experience. (
  • To learn more, download the Transplant in Lymphoma Fact Sheet or Stem Cell Transplant Booklet . (
  • Because stem cell transplant is so dramatically different in prevention in terms of its intensity, in terms of its expanse, and in terms of its treatment-related mortality, that is very informative. (
  • Scientists at VCU Massey Cancer Center's award-winning Bone Marrow Transplant (BMT) Program believe it is, and they recently published several studies that support the possibility of using next-generation DNA sequencing and mathematical modeling to not only understand the variability observed in clinical outcomes of stem cell transplantation, but also to provide a theoretical framework to make transplantation a possibility for more patients who do not have a related donor. (
  • Despite efforts to match patients with genetically similar donors, it is still nearly impossible to predict whether a stem cell transplant recipient will develop potentially fatal graft-versus-host disease (GVHD), a condition where the donor's immune system attacks the recipient's body. (
  • This is called a stem-cell transplant. (
  • stem cell transplantation : Autologous Hematopoietic Stem Cell Transplantation will be performed on all participants randomized to transplant arm. (
  • This study aimed to transplant autologous bone marrow derived mesenchymal stem cells to the patients with liver cirrhosis to assess liver tissue regeneration, efficacy and safety of stem cell therapy and finally to establish an alternative treatment modality to liver transplantation. (
  • Stem cell transplant (also known as bone marrow transplant or BMT) is an established treatment for many cancers and blood diseases once considered incurable. (
  • Ongoing advances in stem cell transplant are expanding its availability and improving outcomes for patients, young and old. (
  • Here at the University of Chicago Medicine, the brightest minds in medicine are ready to meet the needs of all patients considering a stem cell transplant. (
  • We offer the latest promising approaches in blood and bone marrow stem cell transplant. (
  • Recognizing the distinct needs of this population, we've assembled a multidisciplinary team of stem cell transplant and geriatric oncology experts to design a care program tailored specifically for patients over 60. (
  • The Stem Cell Transplant Unit, located on the top floor of the Center for Care and Discovery, offers the newest technology as well as many thoughtful patient and family amenities. (
  • The unit integrates both inpatient and outpatient stem cell transplant care services in one convenient location. (
  • For information about stem cell transplant for children and teens, visit the Pediatric Stem Cell Transplant page on the University of Chicago Comer Children's Hospital website. (
  • transplant procedure for treating mastocytosis-a disease of abnormal mast cell growth. (
  • This study will examine whether a stem cell transplant from a healthy donor can similarly target and destroy mast cells in a "graft-versus-mast cell" effect. (
  • This line will remain in place throughout the transplant and recovery period and will be used to transfuse blood components, administer medicines, infuse the donated stem cells, and draw blood for tests. (
  • Patients will begin conditioning with cyclophosphamide, starting 7 days before the transplant, and fludarabine, starting 5 days before the transplant, to prevent rejection of the donated cells. (
  • In this protocol, we propose to treat patients with advanced forms of mastocytosis with an allogeneic stem cell transplant from an HLA-identical sibling, using a low intensity non-myeloablative regimen. (
  • This approach has the advantage of decreasing the transplant-related toxicity while allowing adequate immunosuppression to establish stem cell and lymphocyte engraftment. (
  • Below is a brief overview of the stem cell transplant process. (
  • Shortly before your child's stem cell transplant, your child will undergo chemotherapy and/or radiation. (
  • 12 It is the care of the patient after transplantation that can present much more of a challenge to the multidisciplinary care team, especially in the setting of allogeneic transplant. (
  • In this article we aim to familiarize primary care practitioners with some of the basics of allogeneic and autologous transplantation, as well as issues relevant to the care of transplant recipients over the short and the long term. (
  • Juliet Barker, Director of Memorial Sloan Kettering's Cord Blood Transplant Program, discusses MSK's expertise in cord blood transplantation. (
  • Because the defect is present in every cell of the body, we did not expect a bone marrow stem cell transplant to be so widespread and effective," says Cherqui. (
  • For instance, if an individual with IPEX has diabetes before transplant, they will still have diabetes after transplant, because the cells in the pancreas that make insulin have been destroyed by this disease, and HSCT cannot replace pancreatic cells. (
  • The transplant itself does not require surgery for the recipient, as the hematopoietic stem cells are typically infused into a large vein in the same way that a patient receives a blood transfusion. (
  • Two days after finishing chemotherapy, you will receive a transplant of stem cells from a sibling. (
  • Hematopoietic cell transplant (HCT) is increasingly used as a treatment for various malignant and non-malignant disease processes. (
  • The history of stem cell transplant goes back as early as 1939, when the first documented clinical transplant was performed. (
  • In 1968, the first successful allogenic stem cell transplant was made possible followed by series of achievements in 1970s and 1980s. (
  • Donor lymphocyte infusion (DLI) has a significant role in relapsed patients with chronic myelogenous leukemia (CML) after stem cell transplant. (
  • The success of collection of mobilized stem cells from peripheral blood was a milestone in the history of transplant. (
  • The fact that Beike has been able to demonstrate safety of transplant by manipulating an established stem cell source is a substantial advancement for the field. (
  • Stem cell transplant (Step 1). (
  • If the transplant is successful, new bone marrow cells will produce healthy red blood cells, white blood cells, and platelets. (
  • In order for the transplant to be successful, certain markers on the blood cells and bone marrow cells must match. (
  • Sarah McInerney (40) has obtained chemotherapy and a stem cell transplant, which is not available in Ireland to treat progressive Multiple Sclerosis. (
  • Cell Transplant. (
  • This study suggests that surface stem cell transplant may become a powerful way to repair damage and restore lost function of auditory pathways. (
  • This is in part dependent on the type of cell transplanted, where the expression of gap junctions such as connexin-43 is essential not only for electromechanical integration, but has also been found to be protective against electrical instability post-transplant. (
  • A stem cell transplant reversed a debilitating neurological disease that causes half of the patients to go blind and lose the ability to walk five years after diagnosis. (
  • Related transplant donors must be proven not to have Fanconi anemia in order for a transplantation to succeed. (
  • Mass lesion is a delayed complication of stem cell transplant. (
  • The preoperative differential diagnosis included mass related to the stem cell transplant, ependymoma, astrocytoma and, less likely, hemangioblastoma. (
  • For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. (
  • All fifty-eight patients, with a median age of 63 and all with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome - a pre-leukemic condition - saw their blood cancers go into remission using a novel combination of low-intensity chemotherapy, targeted radiation delivery by an antibody and a stem-cell transplant. (
  • Both standard and low-dose therapies (a process sometimes known as a "mini transplant" and pioneered at the Hutchinson Center) used to kill leukemia cells in the bloodstream in preparation for a transplant usually require that patients be in remission. (
  • In fact most, if not all, would not been offered a stem cell transplant here or elsewhere. (
  • Sixteen year old girl from Kozhikode, who has been suffering from bone marrow cancer has got a new lease of life, through the stem cells donated by a 55 year old German, in a rare marrow transplant performed at Amrita Institute of Medical Sciences, Kochi. (
  • An autologous transplant uses the patient's own stem cells. (
  • This is possible in the case of certain diseases that do not affect the patient's bone marrow so the doctor can use the patient's healthy cells for the transplant. (
  • An allogeneic transplant uses stem cells collected from another adult. (
  • With a focus on improving the lives of patients living with autoimmune diseases, transplant physician and scientist Dr. Harold Atkins has dedicated his career to discovering innovative methods for stem cell transplantation. (
  • In the late 1990s, Dr. Atkins and neurologist Dr. Mark Freedman proposed a novel way to stop the progression of early aggressive multiple sclerosis (MS) by completely wiping out a patient's immune system, followed by a stem cell transplant. (
  • In this review, we will summarize the role of vitamin D in normal hematopoiesis, discuss ways in which vitamin D may improve outcomes, and discuss a potential role of vitamin D for treating hematologic disorders and modulating the immune system to improve the outcome of allogeneic stem cell transplant. (
  • An early example of a successful peripheral stem cell transplant was carried out in the wake of the 1999 Tokaimura nuclear accident. (
  • Hematopoietic stem cell transplantation ( HSCT ) is the transplantation of multipotent hematopoietic stem cells , usually derived from bone marrow, peripheral blood, or umbilical cord blood. (
  • Autologous HSCT requires the extraction ( apheresis ) of haematopoietic stem cells (HSC) from the patient and storage of the harvested cells in a freezer. (
  • The spectrum of target antigens associated with tumor immunity and alloimmunity after allogeneic HSCT: Host-derived T and B cells can be induced to recognize tumor-associated antigens, whereas donor-derived B and T cells can recognize both tumor-associated antigens and alloantigens. (
  • It is important to note, however, that while the United States Food and Drug Administration (FDA) have approved hematopoietic stem cell transplantation (HSCT) for use against cancer , it is not yet approved for wider use. (
  • Allogeneic HSCT requires a donor to supply suitable stem cells. (
  • Autologous HSCT avoids the issue of trying to find a matching donor because stem cells are harvested from the patients themselves. (
  • Hematopoietic stem cell transplantation (HSCT) has been used as curative treatment in both children and adults for hematologic malignancies, immunodeficiencies, autoimmune disorders, and other rare indications. (
  • In this chapter, we discuss indications for HSCT, conditioning regimens before transplantation, and types of HSCTs. (
  • Increasing rate of incidence is in turn, expected to increase the demand for hematopoietic stem cell transplantation thus, propelling growth of the hematopoietic stem cell transplantation (HSCT) market. (
  • A collaborative research study on hematopoietic stem cell transplantation initiated by World Network for Blood and Marrow Transplantation (WBMN) in 2013 in the domain of promotion of access to hematopoietic stem cell transplantation, developed a donation guidance document, technical and scientific input on safety, and quality of HSCT as mentioned in annual report of the WBMN. (
  • Therefore, the aim of this study was to assess the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the management of AML with GS. (
  • These data suggest that better control of GS prior to allo-HSCT is crucial to improve the outcome of transplantation for those with GS. (
  • However, the optimal therapeutic strategy for GS remains unclear, especially in regards to the indications for need of allogeneic hematopoietic stem cell transplantation (allo-HSCT). (
  • This study included all consecutive adult AML aged over 15 years, excluding patients with acute promyelocytic leukemia, who underwent allo-HSCT for the first time between January 2000 and December 2008 at the nine institutions participating in the Kanto Study Group for Cell Therapy. (
  • Autologous HSCT is performed using the patient's own hematopoietic stem cells, which are harvested before transplantation and reinfused after myeloablation. (
  • Allogeneic HSCT uses human leukocyte antigen (HLA)-matched stem cells derived from a donor. (
  • This article reviews the biology of stem cells, clinical efficacy of HSCT, transplantation procedures, and potential complications. (
  • Cytomegalovirus (CMV) infection remains a significant complication after hematopoietic stem cell transplantation (HSCT) and may have a deleterious impact on the overall outcome after transplantation. (
  • Nutritional status is an important factor influencing outcomes in persons undergoing hematopoietic stem cell transplantation (HSCT). (
  • When PI is likely to cause significant harm or death to someone, allogeneic hematopoietic stem cell transplantation (HSCT) may be the best treatment option. (
  • The person who receives the stem cells is called a recipient of HSCT. (
  • If an allogeneic HSCT is successful, the donor's hematopoietic stem cells will replace the recipient's own cells. (
  • An allogeneic HSCT can replace an individual's own hematopoietic stem cells with stem cells that will produce normal immune system cells. (
  • Allogeneic HSCT also fixes any problems with other blood cells. (
  • Hematopoietic stem cells may be collected from the bone marrow, the peripheral blood, or from umbilical cord blood, so HSCT procedures may be called bone marrow transplants, peripheral blood stem cell transplants, or cord blood transplants depending on the source of the stem cells. (
  • Histocompatible hematopoietic stem cell transplantation (HSCT) was conducted on a 4.5-year-old girl with Niemann-Pick disease type B. The donor was her unaffected brother. (
  • 4.8 If haematopoietic stem cell transplantation (HSCT) is urgent and there are no suitable available donors, assess risk and liaise with the registry. (
  • Hematopoietic stem cell transplantation (HSCT) is an important therapeutic option for some hematological diseases. (
  • Hematopoietic stem cell transplantation (HSCT) is the replacement of a diseased or deficient bone marrow by normal cells, with the aim of reconstituting the marrow and providing immune system control. (
  • To provide an overview of recently published work on autologous hematopoietic stem-cell transplantation (HSCT) in patients with systemic sclerosis (SSc). (
  • HSCT involves the intravenous (IV) infusion of autologous or allogeneic stem cells to re-establish hematopoietic function in patients whose bone marrow or immune system is damaged or defective. (
  • Transplantation of HSC (HSCT) is done in order to re-establish bone marrow and immune system function after being damaged and/or attacked by blood cancer. (
  • The most common indications for HSCT are blood cancers, mainly acute leukaemia, cancers of the lymphatic tissues (lymphomas) and the antibody-forming blood cells (multiple myeloma). (
  • HSCT can be broadly divided into autologous transplantation, where patients use their own blood stem cells, and allogeneic transplantation, where stem cells are obtained from a different person. (
  • Hematopoietic stem cell transplantation (HSCT) is the transplantation of blood stem cells derived from the bone marrow (in this case known as bone marrow transplantation ) or blood. (
  • Hematopoietic stem cell transplantation (HSCT) is an established therapeutic procedure for several congenital and acquired disorders, both malignant and nonmalignant. (
  • Both donor and patient genetic background might influence the success of bone marrow transplantation and could at least partially explain the inter-individual variability in HSCT outcome. (
  • [2] In these cases, the recipient's immune system is usually destroyed with radiation or chemotherapy before the transplantation. (
  • The patient is then treated with high-dose chemotherapy with or without radiotherapy with the intention of eradicating the patient's malignant cell population at the cost of partial or complete bone marrow ablation (destruction of patient's bone marrow's ability to grow new blood cells). (
  • The cells are cleaned and frozen before being reintroduced to the individual after they receive the chemotherapy drugs. (
  • When used to treat cancers such as non-Hodgkin's lymphoma and multiple myeloma, high-dose chemotherapy also destroys normal cells such as the HSCs and HPCs in the bone marrow. (
  • To replenish the lost cells, HSCs and HPCs are routinely harvested from a donor's or patient's blood, and then transplanted back into the patient at the conclusion of the chemotherapy procedure to repopulate the bone marrow. (
  • Next, the patient will undergo high-dose chemotherapy in order to destroy and clear all the harmful immune cells that are attacking the brain and spinal cord. (
  • Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to your body after high-intensity chemotherapy or radiation. (
  • The high-conditioning regimens are meant to severely or completely impair your ability to make stem cells and you will likely experience side effects during the days you receive high-dose conditioning radiation or chemotherapy. (
  • 9 GS was defined as extramedullary tumors that were identified at any time from the diagnosis to transplantation by physical examination and/or imaging studies (computed tomography scan and/or magnetic resonance imaging) and that responded to chemotherapy or irradiation. (
  • We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. (
  • As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation. (
  • Fellows will develop the clinical skills and understanding necessary to become a outstanding provider of care for patients with diseases requiring high-dose chemotherapy and hematopoietic stem cell transplantation. (
  • High-dose chemotherapy treatment can cause significant damage to stem cells in the bone marrow, compromising a person's ability to renew their blood cells. (
  • Because high-dose chemotherapy and stem cell transplantation may place great strain on a patient's body, they are not options for everyone. (
  • The patient is then treated with high-dose chemotherapy with or without radiotherapy in the form of total body irradiation to eradicate the patient's malignant cell population at the cost of also eliminating the patient's bone marrow stem cells, then return of the patient's own stored stem cells to their body. (
  • Patients first receive intensive chemotherapy and radiation to rid the body of cancer cells. (
  • From 1 to 3 days after the chemotherapy is completed, the stem cells will be transfused through the central venous line. (
  • Intrahippocampal transplantation of human neural stem cells resolved all cognitive impairments when animals were tested 1 month after the cessation of chemotherapy. (
  • Granule and pyramidal cell neurons within the dentate gyrus and CA1 subfields of the hippocampus exhibited significant reductions in dendritic complexity, spine density, and immature and mature spine types following chemotherapy, adverse effects that were eradicated by stem cell transplantation. (
  • After completion of chemotherapy, you will receive TBI, and later on the same day, blood stem cells from a donor will be given through the catheter. (
  • Patients undergoing hematopoietic stem cell transplantation receive high doses of chemotherapy and radiotherapy, which cause severe immunosuppression. (
  • The study evaluates the effect of inactivation of the immune system with chemotherapy and immunotherapy and infusion of bone marrow stem cells in early onset type 1 diabetes mellitus. (
  • Because even high doses of irradiation or chemotherapy cannot eradicate all malignant cells in all patients, ever more intensive conditioning regimens dominated efforts in clinical marrow transplantation until the late 1990s. (
  • In contrast to traditional allogeneic stem cell transplantation, in which the patient receives myeloablative conditioning (chemotherapy and/or irradiation), in NST, if donor cells are not infused or are rejected, the recipient's own bone marrow usually recovers spontaneously. (
  • The patient receives chemotherapy to kill blood-forming cells. (
  • The rationale underlying autologous transplantation is to deliver high doses of chemotherapy (with or without radiotherapy). (
  • Stem cells can be destroyed through cancer treatments such as chemotherapy or radiation, as well as and blood-related diseases, such as leukemia, lymphoma, neuroblastoma and multiple myeloma. (
  • Other conditions [13] treated with stem cell transplants include sickle-cell disease , myelodysplastic syndrome , neuroblastoma , lymphoma , Ewing's sarcoma , desmoplastic small round cell tumor , chronic granulomatous disease , Hodgkin's disease and Wiskott-Aldrich syndrome . (
  • In 2006 a total of 50,417 first hematopoietic stem cell transplants were reported as taking place worldwide, according to a global survey of 1327 centers in 71 countries conducted by the Worldwide Network for Blood and Marrow Transplantation. (
  • What are stem cell transplants used to treat? (
  • Stem cell transplants are approved to treat various cancers. (
  • Allogeneic stem cell transplants for patients who are older or have overall poor health are relatively uncommon. (
  • However, reduced intensity allogeneic stem cell transplants may be an appropriate treatment for some older or sicker patients. (
  • We perform both autologous (your own) and allogenic (from a related or unrelated donor) stem cell transplants at King's College Hospital. (
  • Other conditions treated with stem cell transplants include sickle-cell disease , myelodysplastic syndrome , neuroblastoma , lymphoma , Ewing's Sarcoma , Desmoplastic small round cell tumor , Hodgkin's disease , and multiple myeloma . (
  • Allogeneic transplants are also performed using umbilical cord blood as the source of stem cells. (
  • Paired donor exchange kidney transplantation is a process in which unrelated kidney donors are matched to recipients so that compatible transplants can be performed. (
  • Options for individuals lacking a related donor include haplo-cord transplants -- a combination of donated umbilical cord blood stem cells and half-matched (haploidentical) cells from a related donor. (
  • Recipients of stem cell transplants may be severely immunocompromised for many months after transplantation, especially if they are still taking immunosuppressive drugs. (
  • Allogeneic transplantation represents 40% of all stem cell transplants performed annually in Canada and requires donor and recipient matching for major histocompatibility (HLA) antigens. (
  • A clinical trial at MSK has shown that fecal transplants are safe in people who have had stem cell or bone marrow transplants. (
  • The importance of this effect was demonstrated by an increased rate of leukemia relapse in patients receiving transplants in which identical twin donors were used or T cell depletion of donor marrow was performed ( 5 ). (
  • However, in contrast to the 100% donor hematopoietic engraftment typical of myeloablative transplantation, such nonmyeloablative transplants typically resulted in a state of mixed hematopoietic chimerism. (
  • Bone marrow is the traditional source of stem cells for both autologous and homologous transplants. (
  • In the case of transplants using HSC derived from other people, the conditioning therapy also helps reduce the risk of the recipient's body killing or rejecting the incoming donor stem cells (graft rejection). (
  • Another type of HSC source is cord blood cells that are used in umbilical cord blood transplants. (
  • Researchers at UC Santa Cruz have demonstrated a new, rapid method to obtain donor stem cells for bone marrow transplants using a combination of Viagra and a second drug called Plerixafor. (
  • Researchers at King's College London have used single cell RNA sequencing to identify a type of cell that may be able to regenerate liver tissue, treating liver failure without the need for transplants. (
  • As well as using stem cells from a donor's blood, cells from umbilical cord blood can also be used. (
  • Umbilical cord stem cells are less developed than other stem cells, and this means that they can grow into different types of cells. (
  • Umbilical cord blood stem cells are frozen at birth, which is important because they do not suffer any environmental damage or aging. (
  • Umbilical cord blood transplantation has been increasingly used over the past years for both malignant and non-malignant hematologic and other diseases as an alternative to mismatched-related or matched-unrelated bone marrow or peripheral blood hematopoietic stem cell transplantation. (
  • Umbilical cord blood is an alternative hematopoietic stem cell source that can cause various diseases through transplantation. (
  • In two studies presented from researchers at the Keio University School of Medicine in Japan, new sources from menstrual blood-derived endometrial cells and umbilical cord blood-derived mesenchymal cells show significant promise in this function. (
  • In a second study, the same team collected human umbilical cord blood-derived mesenchymal stem cells (UCB-MSC). (
  • Another source of stem cells is the umbilical cord blood of a related or unrelated birth of a child. (
  • Allogeneic stem cell transplantation (infusion of donor stem cells into a patient) is the best-documented curative treatment for select patients with CML at this time. (
  • It may take about a month for the donor stem cells in the bone marrow to begin to function fully. (
  • This is to prevent your body from rejecting the donor stem cells. (
  • The more radiation that can be applied, the more cancer cells will be killed in preparation for donor stem cells to take over the diseased immune system and kill off the remaining cancer cells. (
  • Increasing awareness about stem cell therapies among the population is also expected to propel growth of the hematopoietic stem cell transplantation market. (
  • Plasticell, which specializes in the development of stem cell technologies and cell-based therapies, announced entering into an agreement with Nan yang Technological University (NTU) in Singapore on March 2017, to advance its therapeutic stem cell pipeline. (
  • Also, GE Healthcare announced the introduction of Thaw CB1000, for thawing large volumes of cell therapies cryopreserved in cryo-bags majorly intended for use in research laboratory, in September 2017. (
  • Stem-cell based therapies to strengthen the heart muscle and treat other diseases are beginning to show promise in human clinical trials. (
  • Derive a thorough understanding of the standards of care in clinical transplantation and the role of experimental therapies for high-risk diseases. (
  • Stem cell therapies may be more feasible and less invasive than current therapies. (
  • In this manuscript, the team suggests that by inhibiting peptide generation through immunosuppressive therapies in the earliest weeks following stem cell transplantation, antigen presentation to donor T cells could be diminished, which reduces the risk of GVHD as the recipients reconstitute their T-cell repertoire. (
  • Therefore there is a concerted effort around the world to develop regenerative and alternative therapies, so, stem cell- based therapies are emerging as new alternatives to liver transplantation for end-stage liver pathologies. (
  • It will also explore novel stem cell-based therapies for transplantation in cancer. (
  • Stem cell-based therapies for stroke have expanded substantially over the last decade. (
  • Stem cell regenerative therapies hold promise for treating diseases across the spectrum of medicine. (
  • Both adult stem cells (ASCs) and human pluripotent stem cells (hPSCs) have the potential to facilitate development of cell-based therapies. (
  • However, full clinical translation of stem cell-based therapies has been limited by numerous challenges including the proarrhythmic nature of stem cell derived cardiac grafts. (
  • Although there is legitimate research being done on stem cell therapies, a large industry targets patients in developed countries with unproven treatments, using Internet-based marketing. (
  • One of the major hurdles in the current cell-based therapies is the destructive nature of the standard cell characterization step. (
  • Identify and manage infectious complications of transplantation including suspected and documented bacterial, viral and/or fungal infections. (
  • Manage thrombotic and hemorrhagic complications of transplantation including bleeding, DIC, TTP and deep venous thromboses. (
  • Diagnose and manage other complications of transplantation, including hemorraghic cystitis, diffuse alveolar hemorrhage, veno-occlusive disease and graft failure. (
  • Liver transplantation is still the most effective treatment for the patients with liver cirrhosis, However, serious problems are accompanied with liver transplantation, donor shortage, long waiting list, high cost, risk of rejection, operative complications and complications related to immunosuppressive drugs. (
  • Pulmonary complications are common following hematopoietic cell transplantation (HCT) and contribute significantly to its morbidity and mortality. (
  • This is a presentation from the 2017 Multiprofessional Critical Care Review Course: Adult (MCCRC) on complications of hematopoietic stem cell transplantation and case vignettes. (
  • Physicians in Canada should be aware of stem cell tourism because they may need to counsel patients on transplantation or diagnose complications in those who have had such procedures. (
  • This study provides evidence that mesenchymal stem cell transplantation could favorably impact a side effect of delivery and aging by releasing factors that can influence the urethra and vagina to treat stress urinary incontinence" said Dr Amit N. Patel, director of cardiovascular regenerative medicine at the University of Utah and section editor for Cell Transplantation . (
  • He is a member of the Editorial Board of Journal of Transplantation Technologies & Research and reviewer for Blood and Bone Marrow Transplantation, has authored over 100 scientific publications, and has been awarded multiple research grants, including a $5.7M grant from the California Institute of Regenerative Medicine in 2018. (
  • 1 Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. (
  • 3 Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Lorry I. Lokey Stem Cell Research Building, 265 Campus Drive, Stanford, CA 94305-5461, USA. (
  • The researchers concluded that DPaSCs could provide a source of stem cells for tooth regeneration and repair as well as a wide range of regenerative medicine applications in humans. (
  • Institute of Stem Cell Biology and Regenerative Medicine, Departments of Pathology and Developmental Biology, Stanford University School of Medicine, Stanford, CA 94305, USA. (
  • In the study, the researchers used bone marrow stem cell transplantation to address symptoms of cystinosis in a mouse model. (
  • In 2014, according to the World Marrow Donor Association (WMDA), stem cell products provided for unrelated transplantation worldwide had increased to 20,604 (4,149 bone marrow donations, 12,506 peripheral blood stem cell donations, and 3,949 cord blood units). (
  • 17. The method of claim 1, wherein the hematopoietic system reconstituting cells administered to the recipient are present in a source population of between 1.0 10 8 and 40 10 8 donor cytokine mobilized peripheral blood stem cells/kg of recipient's body weight. (
  • Lack of persistent remission following initial recovery in patients with type 1 diabetes treated with autologous peripheral blood stem cell transplantation. (
  • To assess metabolic control in patients with newly diagnosed type 1 diabetes mellitus who underwent immunoablation followed by autologous peripheral blood stem cell transplantation (APBSCT) as a treat. (
  • The more common way is to collect them from the blood stream, or "peripheral blood stem cell harvesting. (
  • Collecting peripheral blood stem cells provides a bigger graft, does not require that the donor be subjected to general anesthesia to collect the graft, results in a shorter time to engraftment, and may provide for a lower long-term relapse rate. (
  • Hematopoietic stem cell transplantation (bone marrow, cord blood, or peripheral blood stem cells) may cure aplastic anemia and prevent myelodysplastic syndrome or leukemia. (
  • Peripheral blood stem cell transplantation (PBSCT), also called "Peripheral stem cell support", is a method of replacing blood-forming stem cells. (
  • The groundbreaking treatment being trialed is called autologous hematopoietic stem cell transplantation (AHSCT) - a procedure that is currently used to treat cancers of the bone and blood, such as leukemia and multiple myeloma . (
  • Allogeneic stem cell transplantation can be a high-risk procedure. (
  • Bone marrow transplantation (or stem cell transplantation) is a well-established procedure for patients with relapsed or high-risk cancers of the blood, such as leukaemia , lymphoma and myeloma . (
  • Stem cell transplantation is a medical procedure in the fields of hematology and oncology , most often performed for people with diseases of the blood , bone marrow , or certain types of cancer . (
  • Also, from 4 days before the transplantation until about 3 months after the procedure, patients will receive cyclosporine and mycophenolate mofetil-drugs that help prevent both rejection of the donated cells and attack by the donor cells on the patient's cells (called graft-versus-host disease). (
  • Our physicians have been at the forefront of advances in hematopoietic (blood-forming) stem cell transplantation since the procedure was developed decades ago. (
  • The procedure virtually halted the cystine accumulation responsible for the disease, and the cascade of cell death that follows. (
  • A procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person. (
  • A procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor. (
  • This procedure is done if the stem cells in your bone marrow are not functioning or are deficient. (
  • In this procedure, blood is drawn from one arm, which then goes through a machine that filters out stem cells and white blood cells. (
  • After conditioning therapy, stem cells are infused into the bloodstream (usually between 30 and 60 minutes), akin to a blood transfusion procedure. (
  • Hematopoietic stem cell transplantation is currently an inpatient procedure. (
  • Although the patient could not provide an operative report, the surgical team (Lima and colleagues) published their transplantation and surgical procedure. (
  • This therapeutic procedure, known as immunoablation and autologous hematopoietic stem cell transplantation (IAHSCT), continues to be studied by the medical community worldwide. (
  • Canadian Blood Services staff on site at the Ottawa Hospital collected the stem cells (mobilized from the bone marrow into the blood and collected by an apheresis procedure), and then shipped them to Canadian Blood Services' stem cell manufacturing facility for processing. (
  • More than 30 years after its introduction, autologous stem cell transplantation (ASCT) remains the standard of care for young patients with newly diagnosed multiple myeloma. (
  • A previous study whereby the median age of patients was 72 years old concluded that elderly multiple myeloma patients should not be excluded from transplantation displaying good results with melphalan 140 mg/m 2 (ref. 16 ). (
  • Single versus double autologous stem-cell transplantation for multiple myeloma. (
  • Tandem bone marrow transplantation in multiple myeloma. (
  • Our patients see physicians who are experts not only in transplantation but also in the patient's specific cancer or blood disease, such as leukemia, lymphoma and multiple myeloma. (
  • A recent study conducted in mice, baboons, and human volunteers has shown that a non-steroidal anti-inflammatory drug approved by the U.S. Food and Drug Administration (FDA), called meloxicam, significantly increased the number of blood (hematopoietic) stem cells (HSCs) and their descendent hematopoietic progenitor cells (HPCs) entering the circulation from the bone marrow, where they typically reside until needed. (
  • The levels of HSCs and HPCs normally found in blood are very low, and strategies have been devised to mobilize HSCs and progenitor cells out of the bone marrow and into the circulation. (
  • Through the blood test, which the researchers call a 'liquid biopsy,' the researchers monitored human cardiosphere-derived cells (CDCs) and cardiac progenitor cells (CPCs) transplanted into rat hearts following myocardial infarction. (
  • 2019) Circulating exosomes derived from transplanted progenitor cells aid the functional recovery of ischemic myocardium. (
  • A study published by Cell Press June 19th in Stem Cell Reports reveals that simultaneous transplantation of neural and vascular progenitor cells can reduce stroke-related brain damage and improve behavioral recovery in rodents. (
  • Stem cell transplantation represents a promising therapeutic strategy, but transplantation of either neural progenitor cells or vascular cells has shown restricted therapeutic effectiveness. (
  • They induced ischemic stroke in rats and then simultaneously injected neural and vascular progenitor cells from mice into the stroke-damaged rat brains 24 hours later. (
  • This is the first study to use embryonic stem cell-derived vascular progenitor cells together with neural progenitor cells to treat ischemic stroke," Gao says. (
  • Two weeks after stroke, rats that had undergone cotransplantation showed less brain damage and improved behavioral performance on motor tasks compared with rats that had been treated with neural progenitor cells alone. (
  • The role of telomere and telomerase are critical biological features of normal tissue stem and progenitor cells," said Dr. Rho. (
  • However, researchers believe they are close to uncovering one: a stem cell treatment already used for some cancers has enabled wheelchair-bound patients with multiple sclerosis to walk again. (
  • After transplantation, patients are monitored for about 3-4 weeks, during which time they receive antibiotics and transfusions to aid recovery. (
  • Studies have shown that stem cell transplantation could aid in the restoration of brain function in patients with medical conditions such as Parkinson's and Huntington's diseases, and stroke. (
  • The decision to pursue allogeneic transplantation has become more complicated because many patients have very good responses to TKIs. (
  • On the one hand, transplantation has a proven curative track record for some CML patients. (
  • We conducted a retrospective analysis of all known patients suffering from mitochondrial neurogastrointestinal encephalomyopathy who underwent allogeneic haematopoietic stem cell transplantation between 2005 and 2011. (
  • Twenty-four patients, 11 males and 13 females, median age 25 years (range 10-41 years) treated with haematopoietic stem cell transplantation from related (n = 9) or unrelated donors (n = 15) in 15 institutions worldwide were analysed for outcome and its associated factors. (
  • A total of 44 patients (8.7%) had GS before transplantation. (
  • However, we recently reported that adult AML patients with GS had unique characteristics at the time of diagnosis, including younger age, higher white blood cell counts and higher frequency of French-British-American M4 and M5 morphology when compared with those without GS. (
  • We excluded patients with hepatomegaly, splenomegaly or disseminated infiltration of leukemia cells in the skin and the infiltration in the cerebrospinal fluid that did not associated with tumors of the central nervous system. (
  • Before transplantation, patients receive intensive myeloablative chemoradiotherapy followed by stem cell "rescue. (
  • The Stem Cell Transplantation program welcomes the full participation of our patients' health care providers. (
  • This protocol using busulfan, cyclophosphamide and melphalan has been designed as conditioning therapy for patients receiving stem cell transplantation for acute leukemia or myelodysplastic syndrome (MDS). (
  • Patients treated with therapy plan consisting of Busulfan every 6 hours on days -7 through -4, Cyclophosphamide 60 mg/kg/day IV x 2 days, Melphalan 140 mg/m on day -1, antithymocyte globulin (ATG), G-CSF (granulocyte colony-stimulating factor) and stem cell transplantation on day 0. (
  • Certain cancers can be treated by giving patients stem cells that come from someone else. (
  • Some animal-based studies showed that stem cell transplantation could ameliorate liver fibrosis and improve liver functions followed by several clinical trials on human, in patients with advanced liver diseases, these studies demonstrated that stem cell transplantation could significantly reverse hepatic failure with only limited side effects. (
  • This group will include 20 patients with liver cirrhosis , autologous bone marrow derived mesenchymal stem cells will be transplanted to them. (
  • Select patients are candidates for outpatient stem cell transplantation, an approach that offers the full benefits of this life-saving treatment while allowing the patient to spend nights in the comfort of their own home. (
  • Relapse remains the biggest challenge for cancer patients who have undergone stem cell transplantation. (
  • If the mastocytosis persists, patients may receive additional transfusions of donor lymphocytes to help kill the mast cells. (
  • The first transplantation was performed in 1988, it is estimated that approximately 4,000 patients, with malignant and non-malignant diseases, were transplanted withcord blood transplantation. (
  • However, some patients develop a donor immunity-mediated disease known as graft-versus-host-disease following the transplantation. (
  • The researchers then studied colonic biopsies taken from human patients who had received this type of transplantation. (
  • Goblet cells were specifically damaged in patients who developed graft-versus-host-disease, and severe goblet cell loss was associated with a poor survival following the transplantation. (
  • So, administration of IL-25 to protect patients' goblet cells could turn out to be a successful strategy against graft-versus-host-disease after allogeneic hematopoietic stem cell transplantation," said Daigo Hashimoto. (
  • He has dedicated his career to serving the youngest patients, leading research and clinical progress in the treatment of childhood cancers including pediatric stem cell transplantation - experience that will prove invaluable to Cell Source as we continue the development of our Veto Cell platform technologies, which have recently transitioned into the first in human clinical trials. (
  • The patients will receive a nonmyeloablative conditioning regimen with cyclophosphamide and fludarabine, and after this, the cells will be injected intravenously. (
  • The discovery that the infusion of allogeneic hematopoietic stem cells can "rescue" patients from lethal marrow toxicity and give rise to a new donor-derived immunohematopoietic system resulted in successful treatments for patients with malignant or nonmalignant hematologic disease ( 2 , 3 ). (
  • ), reported positive safety data in 114 patients who were treated by doctors at Nanshan Affiliated Hospital of Guangdong Medical College (Shenzhen Nanshan Hospital) in Shenzhen using Beike's proprietary cord blood stem cell transplantation protocol. (
  • Dr. Travis Ye, Beike Biotech's CEO, commented, 'This groundbreaking research is consistent with the safety record we have compiled after providing stem cells for the treatment of more than 8,000 patients. (
  • A new way of transplanting stem cells provides hope for a new therapy for tinnitus and hyperacusis patients. (
  • Stem cells are thought to hold the potential to restore damaged hair cells in the cochlea that contribute to both hearing loss and tinnitus in many patients. (
  • The inability of transplanted cells to structurally and functionally integrate into the host myocardium may pose arrhythmogenic risk to patients. (
  • Supportive care for patients with symptomatic Fanconi anemia includes transfusions of packed RBCs that have been leukodepleted (and are not from family members, to avoid sensitization in case of a future transplantation). (
  • A study by MacMillan et al reported that alternative donor hematopoietic cell transplantation had a high success rate in patients with Fanconi anemia who did not have a history of opportunistic infections or transfusions and who underwent conditioning with single fraction total body irradiation 300 cGy, cyclophosphamide, fludarabine, and antithymocyte globulin. (
  • The study, which involved 130 patients, also found that adding fludarabine to conditioning caused three-fold enhancement of hematopoietic cell engraftment. (
  • A study by Wang et al suggested that in patients with Fanconi anemia, the 1-year overall survival rate following unrelated-donor hematopoietic stem cell transplantation is poor in those with clonal or complete copy gains in the q arm of chromosome 3 or with abnormalities in three or more chromosomes. (
  • Although the only therapy that can cure the pancytopenia is stem cell transplantation, androgens, to which approximately 50-75% of patients respond, are used for those in whom transplantation is not an option. (
  • I built the microinjectors used in these experiments for injecting stem cells into the first human patients. (
  • To test the safety of spinal cord transplantation of human stem cells in patients with amyotrophic lateral sclerosis (ALS) with escalating doses and expansion of the trial to multiple clinical centers. (
  • This study provides Class IV evidence that for patients with ALS, spinal cord transplantation of human stem cells can be safely accomplished and does not accelerate the progression of the disease. (
  • When transplanted into patients, the donor cells should repair and replace the damaged tissues of patients. (
  • Analysis of risk factors for acute cutaneous graft-versus-host disease after allogeneic stem cell transplantation. (
  • Hematopoietic stem cell transplantation was first used as a treatment for some types of cancer but is now widely used as a therapy for various autoimmune diseases. (
  • We now have a tool to determine whether stem cell therapy will be efficacious for an individual patient, not only for the heart but for any organ that received stem cell therapy. (
  • Hematopoietic stem cell transplantation (SCT) is emerging as a safe and effective therapy for HIV-infected persons with hematologic malignancies. (
  • Human immunodeficiency virus (HIV)-infected individuals are at increased risk for a range of hematologic cancers for which stem cell transplantation (SCT) is considered standard therapy. (
  • The Stem Cell Transplantation and Cellular Therapy Department offers specialized training for physicians interested in bone marrow transplantation and stem cell therapy. (
  • Identify appropriateness of stem cell product therapy, growth factor therapy and transfusion medicine as is relevant to transplantation. (
  • Stem cell-based therapy has recently gained attention as a promising treatment for SUI," said study co-author Dr. Margot S. Damaser of the Cleveland Clinic's Department of Biomedical Engineering. (
  • Our results suggest a potential therapy for postpartum SUI," said Dr. Damaser.The group of female rats that received simulated childbirth injury (vaginal distension) and MSCs showed homing of the MSCs to the urethra and vagina, facilitating the recovery of continence.The researchers noted that other kinds of stem cells from different sources have been used in other studies aimed at treating SUI via stem cell transplantation. (
  • In recent years, advances in stem cell biology, have made the prospect of tissue regeneration a potential clinical reality, and several studies have shown the great promise that stem cells hold for therapy. (
  • mesenchymal stem cell based therapy has shown as promising tool in cirrhotic conditions as this type of cells have the ability to differentiate to different cell types including hepatocytes A series of studies have been performed to assess the application of bone marrow derived mesenchymal stem cells to promote liver regeneration and to alleviate cirrhosis. (
  • The conventional treatment is based on the correction of haemoglobin through regular red blood cell transfusions and treating the iron overload that develops subsequently with iron chelation therapy. (
  • Although, early detection and initiations of such supportive treatment has improved the quality of life for people with transfusion-dependent thalassaemia, allogeneic hematopoietic stem cell transplantation is the only widely available therapy with a curative potential. (
  • Randomised controlled trials and quasi-randomised controlled trials comparing hematopoietic stem cell transplantation with each other or with standard therapy (regular transfusion and chelation regimen). (
  • Transplantation of allogeneic (donated) stem cells is a mainstay of therapy for some forms of leukemia. (
  • Washington, May 22 (ANI): Researchers from NewYork-Presbyterian Hospital/Weill Cornell Medical Centre suggest that genetically modifying stem cells prior to transplantation can help minimize the risk associated with the therapy. (
  • Stem cell therapy offers enormous potential to treat and even cure serious diseases. (
  • Researchers said that one of the biggest potential problems with stem cell therapy is the development of tumors. (
  • Once the future stem cell therapist does the therapy, stem cells have the innate potential to produce more cells," he added. (
  • This review will outline the current knowledge, including benefits and challenges, of the many current sources of stem cells for stroke therapy. (
  • Cherqui said that adult bone marrow stem cell therapy is particularly well suited as a potential treatment for cystinosis because these cells target all types of tissues. (
  • Cell Source, Inc. (OTC: CLCS) is a leading innovator of Veto Cell-based cellular therapy and immunotherapy technologies that are designed to provide safer and more accessible bone marrow transplantation, improve the treatment of blood cell cancers, facilitate treatment of genetic diseases, and allow for more accessible and successful organ transplantation by reducing or eliminating the need for lifelong, daily anti-rejection drugs. (
  • This project will contribute to the development of a combined therapy using stem cell grafts with rehabilitative training to optimize locomotor recovery after a severe injury. (
  • The treatment that immediately precedes infusion of HSC is called conditioning therapy and is given to help kill tumour cells, "wipe out the memory" of the recipient's immune system, and create "space" within the bone marrow for the incoming stem cells to grow. (
  • Stem cells are collected (harvested) before conditioning therapy starts and are usually frozen until it is time for use. (
  • Human IDPSCs can be easily derived from dental pulp extracted from adult or 'baby teeth' during routine dental visits," said study lead author Dr. Patricia C.B. Beltrao-Braga of the highly ranked National Institute of Science and Technology in Stem and Cell Therapy in Ribeirao Preto, Brazil. (
  • hIDPSCs are immunologically privileged and can be used in the absence of any immune suppression protocol and have valuable cell therapy applications, including reconstruction of large cranial defects. (
  • Contact: Dr. Patricia C.B. Beltrao-Braga, National Institute of Science and Technology in Stem Cell and Cell Therapy, 2051 Tenente Catao Roxo St. Ribeirao Preto, Brazil. (
  • While significant progress has been made in the preclinical stages, the clinical application of cardiac cell therapy is limited by technical challenges, including inability to isolate a pure population of cardiac-specific progenitors capable of robust engraftment and regeneration, lack of appropriate pre-clinical animal models, uncertainty about the best mode of delivery, paucity of adequate imaging modalities, and lack of knowledge about the fate of transplanted cells. (
  • Some previous research on the efficacy of stem cell therapy for heart repair has shown benefit from mesenchymal stem cells (often found in bone marrow), but mostly because assist in the growth of new blood vessels. (
  • Through discovery, development and applied research, Canadian Blood Services drives world-class innovation in blood transfusion, cellular therapy and transplantation-bringing clarity and insight to an increasingly complex healthcare future. (
  • Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation: Models in Discovery and Translation, Second Edition once again provides clinical and scientific researchers with a deep understanding of the current research in this field and the implications for translational practice. (
  • Because of this, allogeneic transplantation means that not only the donor's blood system but also his or her immune system is transferred. (
  • The benefits of immune restoration remain incompletely characterized but are known to be associated with reduced long-term mortality in general and decreased risk for malignancy specifically, particularly when the CD4 cell count is >500cells/mm3 [23-25]. (
  • More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each year for the treatment of lymphoma, leukemia, immune-deficiency illnesses, congenital metabolic defects, hemoglobinopathies, and myelodysplastic and myeloproliferative syndromes. (
  • This study used MSCs, cells which are believed to be "immune-privileged," with no rejection issues. (
  • The data provides evidence that the way a patient's immune system rebuilds itself following stem cell transplantation is representative of a dynamical system, a system in which the current state determines what future state will follow. (
  • HLA refers to the genes that encode for proteins on the surface of cells that are responsible for regulating the immune system. (
  • These mHA are protein fragments presented on the HLA molecules, which are the receptors on cells' surface to which these fragments of degraded proteins from within a cell bind in order to promote an immune response. (
  • T cells are a family of immune system cells that keep the body healthy by identifying and launching attacks against pathogens such as bacteria, viruses or cancer. (
  • Participants will undergo apheresis to collect lymphocytes (a type of white blood cell) for immune function tests. (
  • Although this important finding is unlikely to impact routine management of HIV infection, it does suggest that reconstitution of a host immune system with a population of mutant cells is a possible avenue of research to explore. (
  • Introduced the use of specific immune T cells to treat life-threatening viral infections. (
  • Introduced immune cell (T cell) depletion to prevent graft-versus-host disease (GVHD) - the most frequent complication after marrow transplantation. (
  • Immune system cells develop from special cells that live in the bone marrow called hematopoietic stem cells. (
  • The donor cells will live in the recipient's bone marrow and make blood and immune system cells. (
  • Immune system cells may be missing or just not work properly. (
  • The immune system uses HLA proteins on cells to help determine which cells belong to the body and which don't, so HLA matching increases the chances of transplanted donor cells being successfully incorporated into the recipient's body. (
  • Allogeneic hematopoietic stem cell transplantation involves transferring immune and haematopoietic system from a healthy donor to the recipient to treat haematological disorders such as leukaemia and lymphoma. (
  • In addition, it weakens the immune system, helping to prevent the rejection of donor marrow or stem cells. (
  • Since the establishment of the autoimmune etiology of type 1 DM in the late 1970s, many clinical trials analyzing the effects of different types of immune interventions demonstrated that beta-cell preservation is an achievable target in different degrees. (
  • The key observation that led to the emergence of nonmyeloablative allogeneic hematopoietic stem cell transplantation (NST) was the discovery of the immune-mediated allogeneic graft-versus-tumor (GVT) effect ( 4 , 5 ). (
  • Because the protocol developed by Beike allows the use of cord blood stem cells without immune suppression, it can be made available to a wide patient population. (
  • Accurate determination of immune system compatibility is vital to minimise graft failure and lethal attack from donor cells against recipient's normal tissues (graft-versus-host disease or GvHD). (
  • Stem cells are part of the immune system that helps to protect the body from viruses and bacteria. (
  • Led by The Ottawa Hospital, a groundbreaking trial called Cellular Immunotherapy for Septic Shock is testing the idea that mesenchymal stem cells may be able to help control the body's immune system to reduce injury and promote healing, while improving its ability to fight infection. (
  • Therefore, to optimize clinical transplantation paradigms, researchers will need to monitor the cells' migration over time to determine the optimal parameters for transplantation. (
  • Such characterization is necessary if the method is to be used to label human stem cells for clinical applications. (
  • The questions we asked were: How does tagging of the human clinical grade stem cells affect their biology? (
  • Stem cell selection is another technique being studied in clinical trials that can reduce the number of T lymphocytes that a patient receives. (
  • Plasticell also announced collaboration with Anthony Nolan, a research organization in blood cancer, to progress clinical development of Plasticell's ex vivo expanded cord blood-derived hematopoietic stem cell product in December 2017. (
  • However, other than observing clinical outcomes, lack of a repeatable, time-sensitive and noninvasive tool to assess the effectiveness of the transplanted cells within the target organ has slowed progress in the stem cell field. (
  • With the development of human embryonic and induced pluripotent stem cell technology, we are optimistic about the potential translation of our research into clinical use. (
  • Identify a problem in clinical transplantation or basic science relevant to transplantation and execute a research project that is likely to lead to publication in a high-quality peer-reviewed journal. (
  • Establishing the safety of implanted embryonic stem cells is crucial before we can move forward with testing these treatments in clinical trials, said Keirstead, an associate professor of anatomy and neurobiology and co-director of UCI s Stem Cell Research Center. (
  • Autologous (self-donated) muscle-derived stem cells have demonstrated therapeutic potential for SUI in animal models and in clinical trials. (
  • Recent clinical trials have confirmed the safety of stem cell delivery to the heart with promising but variable results. (
  • That's been a major issue during pre- clinical research on stem cells because it limits further analyses and biomedical applications . (
  • Canadian Blood Services' stem cell manufacturing program supported the clinical trial , and continues to support treatments. (
  • The blood stem cells used in the clinical trial were autologous, meaning they were collected from the participants themselves. (
  • The clinical trial, supported by our autologous stem cell program, was just published in The Lancet and has received world-wide media attention. (
  • Haematopoietic stem cell transplantation has been proposed as treatment for mitochondrial neurogastrointestinal encephalomyopathy, a rare fatal autosomal recessive disease due to TYMP mutations that result in thymidine phosphorylase deficiency. (
  • Through studies on mice, they found allogeneic haematopoietic stem cell transplantation can lead to a significant reduction in a type of epithelial cell in the colon's inner lining called a goblet cell. (
  • Alternative sources of haematopoietic stem cells, such as HLA mismatched (haplo-identical) family members and cord blood, may be available. (
  • Dr Colin Phipps Diong, Parkway Cancer Centre's new consultant specialising in lymphoma and blood cancers, and haematopoietic stem cell transplantation, explains haematopoietic stem cell transplantation. (
  • The term haematopoietic stem cell (HSC) refers to cells made in the blood factory or bone marrow that have the potential to grow into almost any type of blood cell. (
  • 7 The use of blood stem cells is associated with faster recovery of neutrophils and platelets after transplantation (engraftment) than is the case with bone marrow stem cells. (
  • This section describes the 4 components of allogeneic transplantation - conditioning, transplantation, engraftment and immunoreconstitution ( Fig. 2 ) - and provides information about the patient's hospital stay and the risks associated with this type of transplantation. (
  • Pilot studies of autologous stem cell transplantation using peripheral blood have demonstrated rapid engraftment with this technique. (
  • The reinfusion of the patient's own stem cells acts to rescue the bone marrow from toxicity. (
  • Stem cells are cells produced by the bone marrow that mature into the different blood components-white cells, red cells and platelets. (
  • With the infusion of 5 million CD34+ cells, the recovery time for platelets to a target of 20,000/μL is possible within 2 weeks. (
  • Stem cells produce red blood cells, white blood cells, and platelets. (
  • Myelodysplastic syndromes are a group of bone marrow stem cell disorders marked by ineffective blood cell production and low counts in the peripheral blood. (
  • Sometimes the T lymphocytes attack the cancer cells. (
  • to treat the cancer Abnormal cell growth that cannot be controlled by the body's natural defenses. (
  • than the body would normally tolerate, increasing the probability of killing cancer cells. (
  • In deciding if transplantation is a good option, doctors will consider many factors, including the patient's health status, age, medical history, cancer stage The extent of cancer in the body, including whether the disease has spread from the original site to other body parts. (
  • In autologous stem cell transplantation, stem cells are donated by the patient and collected and frozen before the patient undergoes cancer treatment. (
  • After cancer treatment is given and the cancer cells are believed to be gone, the collected stem cells are reinfused back into the patient. (
  • Stem cell transplantation was pioneered using bone-marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research Center from the 1950s through the 1970s led by E. Donnall Thomas, whose work was later recognized with a Nobel Prize in Physiology and Medicine. (
  • This project will explore the role of novel agents for stem cell treatments in cancer. (
  • Cancer is a disease of the cells, which are the body's basic building blocks. (
  • Efficacy of these treatments depends on the differential deposition of genotoxic damage between cancer cells and normal tissue, with the goal of minimizing injury to normal tissue while maximizing the death of cancer cells. (
  • TBI is designed to damage the DNA (the genetic material of cells) of cancer cells, which may kill the cancer cells. (
  • Cyclophosphamide is designed to interfere with the multiplication of cancer cells, which may slow or stop their growth and spread throughout the body. (
  • This may cause the cancer cells to die. (
  • Fludarabine is designed to make cancer cells less able to repair damaged DNA. (
  • Granulocytic sarcoma (GS) is a tumor consisting of malignant granulocytic precursor cells occurring at anatomical sites other than the bone marrow. (
  • HEMATOPOIETIC STEM CELL TRANSPLANTATION has been used for many years to treat various malignant and nonmalignant hematologic conditions. (
  • Create healthcare diagrams like this example called Leukemia - Stem Cell Transplantation in minutes with SmartDraw. (
  • It then moves on to discuss the immunobiology mechanisms that influence graft-versus-host disease (GVHD), graft-versus-leukemia effect, and transplantation success. (
  • Survival after allogeneic transplantation depends on donor-recipient matching, the graft-versus-host response, and the development of a graft versus leukemia effect. (
  • Donor cell leukemia: reappearance of gene mutations in donor cells - more than an incidental phenomenon? (
  • Animation and slides providing graphic explanation of Bone Marrow Transplantation (BMT)/Stem Cell Transplantation that is done for leukemia and other blood-related disorders. (
  • Wendy Stock, MD, is an expert in leukemia and stem cell transplantation. (
  • A single case report detailed a possible cure resulting from stem-cell transplantation from a CCR5-delta32 homozygous donor (performed to treat acute myelocytic leukemia). (
  • Alemtuzumab is a drug that is designed to specifically attack some types of leukemia and lymphoma cells. (
  • Additional evidence for the role of donor cells in GVT effects came from findings that recurrent leukemia could be successfully treated solely by infusing additional allogeneic lymphocytes ( 6 ). (
  • The increased risk for malignancies was identified as a feature of the early AIDS epidemic, and several malignancies are recognized as AIDS-defining, including Kaposi sarcoma (KS) and certain forms of NHL, including diffuse large B cell lymphoma, Burkitt lymphoma, and primary central nervous system lymphoma [1]. (
  • The B-Cell Lymphoma Moon Shot is revolutionizing the conventional medical research approach to rapidly translate findings into patient treatment options and develop personalized therapeutic strategies. (
  • Rituximab is designed to attach to lymphoma cells, which may cause them to die. (
  • One of the disadvantage of cord blood is its low cell content which limits cord blood transplantation to generally low weight recipients, such as children. (
  • Dr. Wanzhang Yang, who led the study at Nanshan Affiliated Hospital of Guangdong Medical College commented, 'This important study, which is the largest of its kind, demonstrates the safety and efficacy of using cord-blood-derived stem cells to treat a variety of neurological conditions. (
  • However, it also suggests cord-blood-derived stem cells are a safe and viable treatment option for a much broader range of diseases and conditions than previously thought. (
  • The hematopoietic niche of the bone marrow supports the survival and self-renewal of HSCs and HPCs, yet prevents the ill-timed release of these cells into the circulation. (
  • The researchers performed in-depth analysis of the effects of labeling on the stem cells, including its effects on cell proliferation, differentiation, survival and electrophysiology. (
  • This suggested that the transplanted cells could have a beneficial impact when they released trophic factors, agents that stimulate differentiation and survival of cells and then engrafted into the smooth muscle of the urethra and vagina, as demonstrated previously in prior studies. (
  • Ruben Mesa, MD, shares his thoughts on stem cell transplantation related to progression-free survival in MPNs, and Kathy Oubre highlights the importance of good working relationships. (
  • The scientists at Kyoto University discovered that applying new stem cells to the surface of the glial scar rather than underneath it helps their survival. (
  • The survival rate after transplantation from alternative donors is improving, depending on the completeness of the HLA-matching. (
  • Irvine, Calif., July 19, 2006, Transplanting human embryonic stem cells does not cause harm and can be used as a therapeutic strategy for the treatment of acute spinal cord injury, according to a recent study by UC Irvine researchers. (
  • We recognize that stem cell derivations also provide uniquely individual difficulties and limitations in their therapeutic applications. (
  • The key to success in this study was use of a radiolabeled antibody that has therapeutic iodine 131 attached and is designed to target leukemic bloods cells that carry a marker on the surface of the cell known as CD45. (
  • Boston, MA -- ( SBWIRE ) -- 10/24/2012 -- Global Markets Direct's, 'Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2012', provides an overview of the Hematopoietic Stem Cell Transplantation therapeutic pipeline. (
  • This report provides information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. (
  • It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation. (
  • A snapshot of the global therapeutic scenario for Hematopoietic Stem Cell Transplantation. (
  • HSCs are adult stem cells that are made in bone marrow. (
  • They then turned to testing of stem cell behavior and migration in the neonatal and adult rodent brain, performing MRI with a 4.7-T, 40-cm animal scanner system from Varian Inc. of Palo Alto, Calif. They used an imaging protocol consisting of scout imaging in two planes followed by a spin-echo sequence and a 3-D gradient echo scan. (
  • Human adult stem cells need to be investigated in future studies to see if these findings also apply to humans. (
  • The diversity of embryonic and adult tissue sources provides researchers with the ability to harvest an ample supply of stem cells. (
  • A Brazilian and American team of researchers used human immature dental pulp stem cells (IDPSCs) as an alternative source for creating induced pluripotent stem cells (iPSCs), stem cells that can be derived from several kinds of adult tissues. (
  • MSCs, one of the most studied and clinically important populations of adult stem cells, do have shortcomings associated with their isolation and expansion from bone marrow, said study lead author Dr. Gyu-Jin Rho of the College of Veterinary Medicine, Gyeongsang National University, Republic of Korea. (
  • In 2006, scientists discovered a way to "reprogram" mature cells-adult skin cells, for example-into stem cells that could, in principle, give rise to any tissue or organ in the body. (
  • Adult human-induced pluripotent stem cells , which resemble embryonic stem cells , can be used to develop drugs and model diseases, according to the National Institutes of Health. (
  • In fact, adult autologous (as in, using one's own cells) stem cells may be a novel approach for cardiac regeneration after heart attacks. (
  • Nanotechnology developed at Rutgers University-New Brunswick could boost research on stem cell transplantation, which may help people with Alzheimer's disease, Parkinson's disease, other neurodegenerative diseases and central nervous system injuries. (
  • In 2006, 50,417 first HSCTs were recorded worldwide, according to a global survey of 1,327 centers in 71 countries conducted by the Worldwide Network for Blood and Marrow Transplantation. (
  • As per survey by World Network for Blood and Marrow Transplantation (WBMN), around one million hematopoietic stem cell transplantation procedures were performed during 2006 to 2014, which indicates potential opportunities for market players. (
  • Paediatric Blood and Marrow Transplantation Program, Utrecht, The Netherlands. (
  • In this way, they can check to see if a donor's stem cells are the right match. (
  • the donor's stem cells are infused into the patient. (
  • Your child will receive the donor's stem cells through a central line. (
  • If the stem cells will be from the donor's bone marrow, an area of the donor's hip will be cleaned. (
  • If the stem cells will be from the donor's blood, the doctor will stick a needle in the donor's large vein or veins in the arms. (
  • Extrapolation of these methods to humans may enable mild but effective conditioning regimens for transplantation. (
  • Furthermore, the study confirmed previous findings by Keirstead s lab since replicated by four other laboratories around the world that replacing a cell type lost after injury improves the outcome after spinal cord injury in rodents. (
  • But boosting those cells beforehand could improve the outcome. (
  • An injection with a growth factor of goblet cells prior to the transplantation could improve the outcome. (
  • This is a major milestone for Veto Cell technology and our team is optimistic about the potential outcome. (
  • Franca R, Stocco G, Favretto D, Giurici N, Decorti G, Rabusin M. Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children. (
  • Studies suggest that PBSCT has a better outcome in terms of the number of hematopoietic stem cell (CD34+ cells) yield. (
  • Stem cell treatments are still in the experimental stages for treating autoimmune diseases. (
  • Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. (
  • For some types of blood diseases, transplantation is the standard of care. (
  • The science of bone marrow transplantation arose from the realization that irradiation causes lethal bone marrow failure ( 1 ), thus generating the idea that intensifying irradiation or use of cytotoxic drugs at myeloablative doses could cure bone marrow diseases. (
  • Now, treatment of a number of diseases is possible through stem cell transplantation. (
  • While stem cells hold great potential for treating neurodegenerative diseases and central nervous system injuries, controlling and characterizing their fate are critical issues that need to be addressed before their potential use as treatments can be fully realized. (
  • While the promise of personalized medicine and effective treatments for debilitating diseases drive progress in this area, moral and ethical dilemmas about embryonic cells continues to cloud the field. (
  • Prior to stem cell transplantation, subjects will receive CYCLOPHOSPHAMIDE via the central venous line once a day for two days on days -3 and -2. (
  • Stem cell transplantation significantly reduced the number of activated microglia after cyclophosphamide treatment in the brain. (
  • The reinfusion of stem cells will be completed after the last dose of cyclophosphamide, through a peripheral vein. (
  • This review is intended as a basic overview of allogeneic and autologous stem cell transplantation with a special focus on long-term follow-up issues relevant to primary care providers. (
  • I am participating in a Phase I trial testing the use of autologous stem cell transplantation to cure MS. Results in Europe have been very promising, though not perfect. (